


FIGURE 1

**Pool selection**

| Antibody           | Medium    | Selection drug |
|--------------------|-----------|----------------|
| JHL9932 Seq No.1   | TransFx-C | 15P800M        |
| JHL9932 Seq No.2   | TransFx-C | 20P1200M       |
| JHL9932 Seq No.1-1 | BalanCD   | 15P800M        |
| JHL9932 Seq No.2-1 | BalanCD   | 20P1200M       |

FIGURE 2

| Sequence | Medium    | Selection drug | Group |
|----------|-----------|----------------|-------|
| Seq 1    | TransFx-C | 15P800M        | G1    |
|          | TransFx-C | 20P1200M       | G2    |
|          | BalanCD   | 15P800M        | G3    |
|          | BalanCD   | 20P1200M       | G4    |
| Seq 2    | TransFx-C | 15P800M        | G5    |
|          | TransFx-C | 20P1200M       | G6    |
|          | BalanCD   | 15P800M        | G7    |
|          | BalanCD   | 20P1200M       | G8    |
| Seq 1-1  | TransFx-C | 15P800M        | G9    |
|          | TransFx-C | 20P1200M       | G10   |
|          | BalanCD   | 15P800M        | G11   |
|          | BalanCD   | 20P1200M       | G12   |
| Seq 2-1  | TransFx-C | 15P800M        | G13   |
|          | TransFx-C | 20P1200M       | G14   |
|          | BalanCD   | 15P800M        | G15   |
|          | BalanCD   | 20P1200M       | G16   |

**FIGURE 3A**

Seq1- Viability




FIGURE 3B

Seq2- Viability




FIGURE 3C




FIGURE 3D




FIGURE 4

| Sequence | Medium  | Selection drug | Group | Titer (g/L) |
|----------|---------|----------------|-------|-------------|
| Seq 1    | HyCell  | 15P800M        | G1    | 0.620       |
|          | HyCell  | 20P1200M       | G2    | 0.650       |
|          | BalanCD | 15P800M        | G3    | 0.266       |
|          | BalanCD | 20P1200M       | G4    | 0.272       |
| Seq 2    | HyCell  | 15P800M        | G5    | 0.663       |
|          | HyCell  | 20P1200M       | G6    | 0.668       |
|          | BalanCD | 15P800M        | G7    | 0.317       |
|          | BalanCD | 20P1200M       | G8    | 0.305       |
| Seq 1-1  | HyCell  | 15P800M        | G9    | 0.977       |
|          | HyCell  | 20P1200M       | G10   | 0.959       |
|          | BalanCD | 15P800M        | G11   | 0.487       |
|          | BalanCD | 20P1200M       | G12   | 0.446       |
| Seq 2-1  | HyCell  | 15P800M        | G13   | 0.939       |
|          | HyCell  | 20P1200M       | G14   | 0.974       |
|          | BalanCD | 15P800M        | G15   | 0.546       |
|          | BalanCD | 20P1200M       | G16   | 0.572       |

FIGURE 5A




FIGURE 5B




FIGURE 6A




FIGURE 6B




FIGURE 7

| Molecules   | Linker | Pool | Clones | Titer(p/L) | IVCD     | Qe(pg/cell/day) | Day12 viability | Monoclonality |
|-------------|--------|------|--------|------------|----------|-----------------|-----------------|---------------|
| Seq No. 1-1 | 11 aa  | G10  | 9A7    | 0.66       | 1.31E+08 | 11.6            | 57              | Yes           |
|             |        |      | 9C7    | 1.08       | 1.04E+08 | 15.5            | 70              | Yes           |
|             |        |      | 9D6    | 1.45       | 1.65E+08 | 19.8            | 73              | Yes           |
|             |        |      | 9F8    | 0.90       | 1.39E+08 | 18.3            | 49              | Yes           |
|             |        |      | 9G2    | 0.75       | 1.29E+08 | 13.7            | 55              | Yes           |
|             |        |      | 10C9   | 0.60       | 1.29E+08 | 12.6            | 48              | Yes           |
|             |        |      | 10E9   | 0.96       | 1.12E+08 | 12.9            | 74              | Yes           |
|             |        |      | 10G5   | 1.16       | 1.22E+08 | 17.8            | 65              | Yes           |
|             |        |      | 9C5    | 1.26       | 1.18E+08 | 17.6            | 72              | Yes           |
|             |        |      | 9C9    | 1.38       | 1.48E+08 | 21.5            | 64              | Yes           |
|             |        |      | 10C11  | 0.77       | 1.18E+08 | 13.0            | 59              | Yes           |
| Seq No. 2-1 | 16 aa  | G14  | 10G11  | 0.69       | 9.99E+07 | 12.4            | 56              | Yes           |
|             |        |      | 13B4   | 1.34       | 1.26E+08 | 24.3            | 55              | Yes           |
|             |        |      | 13C8   | 1.20       | 1.33E+08 | 17.8            | 67              | Yes           |
|             |        |      | 13C11  | 1.46       | 1.43E+08 | 21.7            | 67              | Yes           |
|             |        |      | 13E3   | 1.41       | 1.39E+08 | 22.4            | 63              | Yes           |
|             |        |      | 14B9   | 1.74       | 1.34E+08 | 24.8            | 70              | Yes           |
|             |        |      | 14C8   | 1.35       | 1.39E+08 | 18.8            | 72              | Yes           |
|             |        |      | 14C10  | 1.42       | 1.50E+08 | 24.5            | 58              | Yes           |
|             |        |      | 14D8   | 1.43       | 1.62E+08 | 21.7            | 66              | Yes           |
|             |        |      | 14E11  | 1.54       | 1.64E+08 | 23.3            | 66              | Yes           |
|             |        |      | 14F2   | 0.98       | 1.57E+08 | 16.7            | 59              | Yes           |
|             |        |      | 14F8   | 1.34       | 1.50E+08 | 23.5            | 57              | Yes           |
|             |        |      | 14B2   | 1.44       | 1.28E+08 | 23.9            | 60              | Yes           |
|             |        |      | 14E5   | 1.27       | 1.27E+08 | 18.4            | 69              | Yes           |
|             |        |      | 13F7   | 0.85       | 1.16E+08 | 14.2            | 60              | Yes           |
|             |        |      | 13D4   | 1.09       | 1.06E+08 | 16.4            | 66              | Yes           |
|             |        |      | 13D7   | 1.30       | 1.60E+08 | 21.3            | 61              | Yes           |
|             |        |      | 13F10  | 1.61       | 1.35E+08 | 21.4            | 75              | Yes           |
|             |        |      | 14E1   | 1.41       | 1.66E+08 | 23.0            | 61              | Yes           |
|             |        |      | 14A5   | 1.46       | 1.59E+08 | 19.9            | 73              | Yes           |




FIGURE 8B





FIGURE 9A






FIGURE 10

| Molecule    | Linker | Pept | Class | Therap.I | IC <sub>50</sub> | Cytotoxicity | Days of stability | Biocompatibility |
|-------------|--------|------|-------|----------|------------------|--------------|-------------------|------------------|
| Seq No. 1-1 | 11 aa  | G10  | 9C7   | 1.08     | 1.04E+08         | 15.5         | 70                | Yes              |
|             |        |      | 9D6   | 1.45     | 1.65E+08         | 19.8         | 73                | Yes              |
|             |        |      | 10G5  | 1.16     | 1.22E+08         | 17.8         | 65                | Yes              |
|             |        |      | 9C5   | 1.26     | 1.18E+08         | 17.6         | 72                | Yes              |
|             |        |      | 9C9   | 1.38     | 1.48E+08         | 21.5         | 64                | Yes              |
| Seq No. 2-1 | 16 aa  | G14  | 13C11 | 1.46     | 1.43E+08         | 21.7         | 67                | Yes              |
|             |        |      | 14B9  | 1.74     | 1.34E+08         | 24.8         | 70                | Yes              |
|             |        |      | 14E11 | 1.54     | 1.64E+08         | 23.3         | 66                | Yes              |
|             |        |      | 13F10 | 1.61     | 1.35E+08         | 21.4         | 75                | Yes              |
|             |        |      | 14A5  | 1.46     | 1.59E+08         | 19.9         | 73                | Yes              |

**FIGURE 11**

| AD Receive number | Sample Name | Rel. Potency (%) | EC50 (ng/ml) |
|-------------------|-------------|------------------|--------------|
| R-AD-20-053-01    | G1          | 135.3            | 22.33        |
| R-AD-20-053-02    | G2          | 135.8            | 17.71        |
| R-AD-20-053-03    | G5          | 138.1            | 17.65        |
| R-AD-20-053-04    | G6          | 137.9            | 17.37        |
| R-AD-20-053-05    | G9          | 98.7             | 20.98        |
| R-AD-20-053-06    | G10         | 131.2            | 15.79        |
| R-AD-20-053-07    | G13         | 127.7            | 16.23        |
| R-AD-20-053-08    | G14         | 127.4            | 16.26        |

FIGURE 12





FIGURE 13



|      |            |       |       |       |       |       |       |       |       |             |
|------|------------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|
|      | G9 (as RS) | G1    | G2    | G5    | G6    | G9    | G10   | G13   | G14   | G9 (as SST) |
| Mean | 22.33      | 17.71 | 17.65 | 17.37 | 17.37 | 20.98 | 15.79 | 16.23 | 16.26 | 21.77       |

|                          |            |       |       |       |       |       |       |       |       |             |
|--------------------------|------------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|
|                          | G9 (as RS) | G1    | G2    | G5    | G6    | G9    | G10   | G13   | G14   | G9 (as SST) |
| Coefficient of variation | 8.39%      | 0.84% | 1.16% | 4.52% | 0.16% | 0.30% | 1.05% | 2.22% | 1.96% | 8.12%       |

**FIGURE 14**

| AD Receive number | Sample Name | Ref. Potency (%) | EC50 (ng/mL) |
|-------------------|-------------|------------------|--------------|
| R-AD-20-053-01    | G1          | 126.0            | 51.9         |
| R-AD-20-053-02    | G2          | 132.3            | 49.4         |
| R-AD-20-053-03    | G5          | 137.8            | 48.6         |
| R-AD-20-053-04    | G6          | 131.3            | 51.1         |
| R-AD-20-053-05    | G9          | 104.1            | 66.9         |
| R-AD-20-053-06    | G10         | 129.0            | 54.0         |
| R-AD-20-053-07    | G13         | 129.5            | 52.3         |
| R-AD-20-053-08    | G14         | 127.2            | 53.5         |

FIGURE 15A




FIGURE 15B




**FIGURE 16**

| AD Receive number | Sample Name | Rel. Potency (%) | EC50 (ng/ml) |
|-------------------|-------------|------------------|--------------|
| R-AD-20-053-01    | G1          | 108.9            | 42.49        |
| R-AD-20-053-02    | G2          | 109.1            | 42.53        |
| R-AD-20-053-03    | G5          | 128.7            | 35.91        |
| R-AD-20-053-04    | G6          | 120.8            | 38.25        |
| R-AD-20-053-05    | G9          | 101.6            | 47.16        |
| R-AD-20-053-06    | G10         | 135.2            | 35.37        |
| R-AD-20-053-07    | G13         | 130.4            | 36.79        |
| R-AD-20-053-08    | G14         | 142.3            | 33.71        |

FIGURE 17A





FIGURE 17B



|      |            |       |       |       |       |       |       |       |       |
|------|------------|-------|-------|-------|-------|-------|-------|-------|-------|
|      | G9 (as RS) | G1    | G2    | G5    | G6    | G9    | G10   | G13   | G14   |
| Mean | 46.98      | 42.49 | 42.53 | 35.91 | 38.25 | 47.16 | 35.37 | 36.79 | 33.71 |

|                          |            |       |        |       |       |       |       |       |        |
|--------------------------|------------|-------|--------|-------|-------|-------|-------|-------|--------|
|                          | G9 (as RS) | G1    | G2     | G5    | G6    | G9    | G10   | G13   | G14    |
| Coefficient of variation | 2.74%      | 6.27% | 10.06% | 2.68% | 1.61% | 8.23% | 6.96% | 9.98% | 10.17% |

FIGURE 18




**FIGURE 19A****Groups, Dose Concentrations and Dose Volumes**

| Group | Number of animals | Animal number | Treatment                 | Concentration       | Dose volume     |
|-------|-------------------|---------------|---------------------------|---------------------|-----------------|
| 1     | 10                | 1-10          | Vehicle                   | 0                   | 150ul           |
| 2     | 11                | 11-21         | AB002                     | 2.5 and 1mg/kg      | 150ul           |
| 3     | 10                | 22-31         | $\alpha$ PD-1 Ab          | 5mg/kg              | 150ul           |
| 4     | 10                | 32-41         | $\alpha$ PD-1 Ab / IL-15  | 5mg/kg,<br>2.5mg/kg | 150ul+<br>150ul |
| 5     | 10                | 42-51         | $\alpha$ PD-L1 Ab         | 5mg/kg              | 150ul           |
| 6     | 10                | 52-61         | $\alpha$ PD-L1 Ab / IL-15 | 5mg/kg,<br>2.5mg/kg | 150ul+<br>150ul |
| 9     | 10                | 82-91         | IL-15                     | 2.5mg/kg            | 150ul           |


**FIGURE 19B****Groups, Dose Schedules.**

| Group | Treatment                 | Dose Schedules     |
|-------|---------------------------|--------------------|
| 1     | Vehicle                   | Biweekly           |
| 2     | AB002                     | Day 5, 8           |
| 3     | $\alpha$ PD-1 Ab          | Biweekly           |
| 4     | $\alpha$ PD-1 Ab / IL-15  | Biweekly/ Day 5, 8 |
| 5     | $\alpha$ PD-L1 Ab         | Biweekly           |
| 6     | $\alpha$ PD-L1 Ab / IL-15 | Biweekly/ Day 5, 8 |
| 9     | IL-15                     | Biweekly           |

**FIGURE 19C**

|          | Vehicle | AB002 | $\alpha$ PD-1 | $\alpha$ PD-1<br>+IL-15 | $\alpha$ PD-L1 | $\alpha$ PD-L1<br>+IL-15 | IL-15 |
|----------|---------|-------|---------------|-------------------------|----------------|--------------------------|-------|
| N Number | 10      | 11    | 10            | 10                      | 10             | 10                       | 10    |
| Minimum  | 991.5   | 0.000 | 0.000         | 0.000                   | 0.000          | 0.000                    | 216.8 |
| Maximum  | 2025    | 144.2 | 1773          | 246.6                   | 2371           | 709.0                    | 1358  |
| Range    | 1034    | 144.2 | 1773          | 246.6                   | 2371           | 709.0                    | 1141  |
| Mean     | 1416    | 13.11 | 686.8         | 120.4                   | 910.0          | 427.7                    | 791.0 |
| SD       | 396.9   | 43.49 | 577.3         | 97.22                   | 736.2          | 221.7                    | 312.6 |
| SEM      | 125.5   | 13.11 | 182.5         | 30.74                   | 232.8          | 70.11                    | 98.86 |

FIGURE 20








FIGURE 22

A

| Group | No. of mice | Treatment | Dose level (mg/kg) | Dosing Solution (mg/ml) | Dosing Volume ( $\mu$ L/g) | ROA  | Dosing Frequency & Duration |
|-------|-------------|-----------|--------------------|-------------------------|----------------------------|------|-----------------------------|
| 1     | 10          | AB002     | 1                  | 0.1                     | 10                         | i.p. | Q3D $\times$ 3w             |
| 2     | 10          | AB002     | 2.5                | 0.25                    | 10                         | i.p. | Q3D $\times$ 3w             |
| 3     | 10          | Anti-mPD1 | 10                 | 1                       | 10                         | i.p. | Q3D $\times$ 3w             |

B






FIGURE 23



C

PD-1 inhibitors Combination Study Tumor Growth



D

PD-1 inhibitor Combination Study  
Terminal Tumor Volume




**FIGURE 24****Wild Type ECD of Human PD-1 without the First Four Amino Acids (SEQ ID NO:1)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPFE  
DRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAISLAPKAQIKESLRAELR  
VTERRAEVPTAHPSPSPRPAGQFQTLV

**sPD-1 variant 1: S38G/S63G/P65L/N92S/G100S/S103V/A108I/A116V (SEQ ID NO:2)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSEGFVLNWYRMSPSNQTDKLAAPFE  
EDRGQLGQDCRFRVTQLPNGRDFHMSVVRARRSDSGTYLCSAIVLAPKIQIKESLRVEL  
RVTERRAEVPTAHPSPSPRPAGQFQTLV

**sPD-1 variant 2: S38G/S63G/P65L/G100S/S103V/A108I/A116V (SEQ ID NO:3)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSEGFVLNWYRMSPSNQTDKLAAPFE  
EDRGQLGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRVEL  
RVTERRAEVPTAHPSPSPRPAGQFQTLV

**sPD-1 variant 3: P65L/G100S/S103V/A108I/A116V (SEQ ID NO:4)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPFE  
DRSQLGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRVELR  
VTERRAEVPTAHPSPSPRPAGQFQTLV

**sPD-1 variant 4: S63G/G100S/S103V/A108I/A116V (SEQ ID NO:5)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPFE  
DRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRVEL  
RVTERRAEVPTAHPSPSPRPAGQFQTLV

**sPD-1 variant 5: S63G/P65L/G100S/S103V/A108I/A116V (SEQ ID NO:6)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPFE  
DRGQLGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRVELR  
VTERRAEVPTAHPSPSPRPAGQFQTLV

**sPD-1 variant 6: G100S/S103V/A108I/A116V (SEQ ID NO:7)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPFE  
DRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRVELR  
VTERRAEVPTAHPSPSPRPAGQFQTLV

**sPD-1 variant 7: G100S/S103V/A108I (SEQ ID NO:8)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPFE  
DRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRAELR  
VTERRAEVPTAHPSPSPRPAGQFQTLV

**sPD-1 variant 8: N92S/G100S/S103V/A108I/A116V (SEQ ID NO:9)**

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPFE  
DRSQPGQDCRFRVTQLPNGRDFHMSVVRARRSDSGTYLCSAIVLAPKIQIKESLRVELRV  
TERRAEVPTAHPSPSPRPAGQFQTLV

**FIGURE 25****Human IL-15 domain (SEQ ID NO:10)**

NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELQVISLESGDASIH  
DTVENLHILANNSLSSNGNVTESGCKECEEELEEKNIKEFLQSFVHIVQMFINTS

**Human IL-15R alpha sushi domain (SEQ ID NO:11)**

ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTTPS  
LKCIR

**Linker (SEQ ID NO:12)**

SGGSGGGGSGGGSGGGGSLQ

**Linker variant 1 (SEQ ID NO:13)**

SGGGGSGGGGSGGGSGGSGQ

**Linker variant 2 (SEQ ID NO:14)**

SGGGGSGGGGSGGGSGGSGQ

**Linker variant 3 (SEQ ID NO:15)**

SGGGGSGGGGSGGGSGGSQ

**Linker variant 4 (SEQ ID NO:16)**

SGGGGSGGGGSGGGSGGSLQ

**Linker variant 5 (SEQ ID NO:17)**

SGGGGSGGGGSGGGSGGSLQ

**Linker variant 6 (SEQ ID NO:18)**

SGGGGSGGGGSGGGSGGSLQ

**GS Linker (SEQ ID NO:19)**

GGSGGGGS

**GS Linker X2 (SEQ ID NO:20)**

SGGGGSGGGGS

**GS Linker X3 (SEQ ID NO:21)**

SGGGGSGGGGSGGGGS

**Signal Peptide 1 (SEQ ID NO:22)**

MAPRRARGCRTLGLPALLLLLLLRPPATRG

**Signal peptide 2 (SEQ ID NO:23)**

MDMRVPAQLLGLLLWLRGARC

**FIGURE 26****Human IgG4 (SEQ ID NO:24)**

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS  
GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSV  
FLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNST  
YRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEM  
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRW  
QEGNVFSCSVMHEALHNHYTQKSLSLGLGK

**Variant Human IgG4 (SEQ ID NO:25)**

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS  
GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSV  
FLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNST  
YRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEM  
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRW  
QEGNVFSCSVMHEALHNHYTQKSLSLGLGK

## FIGURE 27A

## Fusion Protein 1 with Linker variant 1 and GS linker X2 (SEQ ID NO:26)

Human IL-15R alpha sushi + *Linker variant 1* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X2* + sPD-1 variant

ITCPPPMSEVHADIWVKSYSLSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGGSGGGGSGGGGSGGSGQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPSCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGSLDSPDRPWNPPTEFPALLVYTE  
GDNATFTCSFNTSESEFVLNWMSPSNQTDKLAAPEDRSQPGQDCRERYTQLPN  
GRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPS  
PRPAGQFOTLV

## Fusion Protein 2 with Linker variant 2 and GS linker X2 (SEQ ID NO:27)

Human IL-15R alpha sushi + *Linker variant 2* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X2* + sPD-1 variant

ITCPPPMSEVHADIWVKSYSLSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGGSGGGGSGGGGSGGSGQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPSCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGSLDSPDRPWNPPTEFPALLVYTE  
GDNATFTCSFNTSESEFVLNWMSPSNQTDKLAAPEDRSQPGQDCRERYTQLPN  
GRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPS  
PRPAGQFOTLV

## FIGURE 27B

Fusion Protein 3 with Linker variant 3 and GS linker X2 (SEQ ID NO:28)

Human IL-15R alpha sushi + *Linker variant 3* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X2* + sPD-1 variant

ITCPPPMSEVHADIWVKSYSLSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGGSGGGGSGGGGSGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPSCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGSLDSPDRPWNPPTEFPALLVYTE  
GDNATFTCSFNTSESEFVLNWMSPSNQTDKLAAPEDRSQPGQDCRERVTLQPN  
GRDFHMSVVRARRNDSTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPS  
PRPAGQFOTLV

Fusion Protein 4 with Linker variant 4 and GS linker X2 (SEQ ID NO:29)

Human IL-15R alpha sushi + *Linker variant 4* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X2* + sPD-1 variant

ITCPPPMSEVHADIWVKSYSLSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGGSGGGGSGGGGSGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPSCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGSLDSPDRPWNPPTEFPALLVYTE  
GDNATFTCSFNTSESEFVLNWMSPSNQTDKLAAPEDRSQPGQDCRERVTLQPN  
GRDFHMSVVRARRNDSTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPS  
PRPAGQFOTLV

## FIGURE 27C

Fusion Protein 5 with Linker variant 5 and GS linker X2 (SEQ ID NO:30)

Human IL-15R alpha sushi + *Linker variant 5* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X2* + sPD-1 variant

ITCPPPMSEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGSGGGSGGGSGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGSGGGGSLDSPDRPWNPPTEFPALLVYTE  
GDNATFTCSFNTSESEFVLNWMSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPN  
GRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPS  
PRPAGQFQTLV

Fusion Protein 6 with Linker variant 6 and GS linker X2 (SEQ ID NO:31)

Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X2* + sPD-1 variant

ITCPPPMSEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGSGGGSGGGSGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGSGGGGSLDSPDRPWNPPTEFPALLVYTE  
GDNATFTCSFNTSESEFVLNWMSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPN  
GRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPS  
PRPAGQFQTLV

## FIGURE 27D

**Fusion Protein 7 with Linker variant 1 and GS linker X3 (SEQ ID NO:32)**

**Human IL-15R alpha sushi** + *Linker variant 1* + **Human IL-15** + GS linker + Human IgG4 Fc  
+ *GS linker X3* + **sPD-1 variant**

ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGGSGGGGSGGGGSGGSGQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGSGGGGSLDSPDRPWNPTESPALL  
VVTEGDNATFTCSFNTSESEVFNWYRMSPSNQTDKLAAPEDRSQPGQDCRERV  
QLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTA  
HPSPSPRPAGQFQTLV

**Fusion Protein 8 with Linker variant 2 and GS linker X3 (SEQ ID NO:33)**

**Human IL-15R alpha sushi** + *Linker variant 2* + **Human IL-15** + GS linker + Human IgG4 Fc  
+ *GS linker X3* + **sPD-1 variant**

ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGGSGGGGSGGGGSGGSGQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGSGGGGSLDSPDRPWNPTESPALL  
VVTEGDNATFTCSFNTSESEVFNWYRMSPSNQTDKLAAPEDRSQPGQDCRERV  
QLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTA  
HPSPSPRPAGQFQTLV

## FIGURE 27E

Fusion Protein 9 with Linker variant 3 and GS linker X3 (SEQ ID NO:34)

Human IL-15R alpha sushi + *Linker variant 3* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X3* + sPD-1 variant

ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGGSGGGGSGGGGSGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGSGGGGSLDSPDRPWNPTESPALL  
VVTEGDNATFTCSFNTSESEVFNWYRMSPSNQTDKLAAPEDRSQPGQDCRERV  
QLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTA  
HPSPSPRPAGQFQTLV

Fusion Protein 10 with Linker variant 4 and GS linker X3 (SEQ ID NO:35)

Human IL-15R alpha sushi + *Linker variant 4* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X3* + sPD-1 variant

ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGGSGGGGSGGGGSGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGSGGGGSLDSPDRPWNPTESPALL  
VVTEGDNATFTCSFNTSESEVFNWYRMSPSNQTDKLAAPEDRSQPGQDCRERV  
QLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTA  
HPSPSPRPAGQFQTLV

## FIGURE 27F

Fusion Protein 11 with Linker variant 5 and GS linker X3 (SEQ ID NO:36)

Human IL-15R alpha sushi + *Linker variant 5* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X3* + sPD-1 variant

ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGSGGGSGGGSGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGSGGGSGGGSLDSPDRPWNPTESPALL  
VVTEGDNATFTCSFNTSESEVFNWYRMSPSNQTDKLAAPEDRSQPGQDCRERV  
QLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTA  
HPSPSPRPAGQFQTLV

Fusion Protein 12 with Linker variant 6 and GS linker X3 (SEQ ID NO:37)

Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15 + GS linker + Human IgG4 Fc  
+ *GS linker X3* + sPD-1 variant

ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTPSLKCIRSGGGSGGGSGGGSGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDV  
HPCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEL  
EEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMEALHNHYTQKSLSLGLKSGGGSGGGSGGGSLDSPDRPWNPTESPALL  
VVTEGDNATFTCSFNTSESEVFNWYRMSPSNQTDKLAAPEDRSQPGQDCRERV  
QLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTA  
HPSPSPRPAGQFQTLV

## FIGURE 28A

**Preprotein 1 including Signal Peptide 1 and Fusion protein 1 (SEQ ID NO: 38)**

Signal peptide + **Human IL-15R alpha sushi** + *Linker variant 1* + **Human IL-15** + GS linker + Human IgG4 Fc + *GS linker X2* + **sPD-1 variant**

MAPRRARGCRTLGLPALLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYIC  
NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSGQ  
NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELOVISLESGDASIH  
DTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTSGGSGGG  
GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
GSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSN  
QTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDEFHMSVVRARRNDSGTYLCSAIVLAP  
KIQIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

**Preprotein 2 including Signal Peptide 1 and Fusion protein 2 (SEQ ID NO: 39)**

Signal peptide + **Human IL-15R alpha sushi** + *Linker variant 2* + **Human IL-15** + GS linker + Human IgG4 Fc + *GS linker X2* + **sPD-1 variant**

MAPRRARGCRTLGLPALLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYIC  
NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSGQ  
NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELOVISLESGDASIH  
DTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTSGGSGGG  
GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
GSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSN  
QTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDEFHMSVVRARRNDSGTYLCSAIVLAP  
KIQIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

## FIGURE 28B

**Preprotein 3 including Signal Peptide 1 and Fusion protein 3 (SEQ ID NO: 40)**

Signal peptide + Human IL-15R alpha sushi + *Linker variant 3* + Human IL-15 + GS linker + Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MAPRRARGCRTLGLPALLLLLLLLRPPATRGI**TCPPPM**SVEHADIWVKSYSLYSRERYIC  
**NSGFKRKAGTSSLTECVLNKATNV**AHWT**TPSLKCIR***SGGGGSGGGGSGGGGSGGSQ*  
*NWVNVISDLKKIEDLIQSMHIDATLYTESDVHP*SCKVTAMK**CFLLELOVISLES**GDASIH  
**DTVENLIILANNSLSSNGNV**TESG**CKECEELEE**KN**IK**EF**LOS**FBHIVQMFINT**SGGSGGG**  
 GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
 WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
 TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLGK**SGGG**  
**GSGGGGSLDSPDRPWN**PPT**ESP**ALLV**TEGD**NAT**FTC**SE**SNTSE**SE**SVLN**WYRM**SPSN**  
**QTDKLA**AF**PEDRSOPG**OD**CRFR**VT**QLPNGR**DE**HMSVVR**ARRND**SGTYLCS**AI**VLAP**  
**KIQIKESLR**VELRV**TERRAEVPTA**HPSPSPRPAG**QFOTLV**

**Preprotein 4 including Signal Peptide 1 and Fusion protein 4 (SEQ ID NO: 41)**

Signal peptide + Human IL-15R alpha sushi + *Linker variant 4* + Human IL-15 + GS linker + Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MAPRRARGCRTLGLPALLLLLLLLRPPATRGI**TCPPPM**SVEHADIWVKSYSLYSRERYIC  
**NSGFKRKAGTSSLTECVLNKATNV**AHWT**TPSLKCIR***SGGGGSGGGGSGGGGSGGSLQN*  
*WVNVISDLKKIEDLIQSMHIDATLYTESDVHP*SCKVTAMK**CFLLELOVISLES**GDASIH  
**TVENLIILANNSLSSNGNV**TESG**CKECEELEE**KN**IK**EF**LOS**FBHIVQMFINT**SGGSGGG**  
 GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
 WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
 TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLSLGK**SGGG**  
**GSGGGGSLDSPDRPWN**PPT**ESP**ALLV**TEGD**NAT**FTC**SE**SNTSE**SE**SVLN**WYRM**SPSN**  
**QTDKLA**AF**PEDRSOPG**OD**CRFR**VT**QLPNGR**DE**HMSVVR**ARRND**SGTYLCS**AI**VLAP**  
**KIQIKESLR**VELRV**TERRAEVPTA**HPSPSPRPAG**QFOTLV**

## FIGURE 28C

**Preprotein 5 including Signal Peptide 1 and Fusion protein 5 (SEQ ID NO: 42)**

Signal peptide + **Human IL-15R alpha sushi** + *Linker variant 5* + **Human IL-15** + GS linker + Human IgG4 Fc + *GS linker X2* + **sPD-1 variant**

MAPRRARGCRTLGLPALLLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYIC  
 NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGSGGGSGGGSGGGSLQN  
 WVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIH  
 TVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTEGGSGGG  
 GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
 WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
 TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
 GSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSN  
 QTDKLAAPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAP  
 KIQIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

**Preprotein 6 including Signal Peptide 1 and Fusion protein 6 (SEQ ID NO: 43)**

Signal peptide + **Human IL-15R alpha sushi** + *Linker variant 6* + **Human IL-15** + GS linker + Human IgG4 Fc + *GS linker X2* + **sPD-1 variant**

MAPRRARGCRTLGLPALLLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYIC  
 NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGSGGGSGGGSGGGSLQ  
 NWNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIH  
 DTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTEGGSGGG  
 GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
 WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
 KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
 TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
 GSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSN  
 QTDKLAAPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAP  
 KIQIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

## FIGURE 28D

**Preprotein 7 including Signal Peptide 1 and Fusion protein 7 (SEQ ID NO: 44)**

Signal peptide + **Human IL-15R alpha sushi** + *Linker variant 1* + **Human IL-15** + GS linker + Human IgG4 Fc + *GS linker X3* + **sPD-1 variant**

MAPRRARGCRTLGLPALLLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYIC  
NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSGQ  
NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIH  
DTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTSGGSGGG  
GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
GSGGGGSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFNTSESEFVLNWYR  
MSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCS  
AIVLAPKIQIKESLRVELRVTERRAEYPTAHPSPSRPAGQFOTLY

**Preprotein 8 including Signal Peptide 1 and Fusion protein 8 (SEQ ID NO: 45)**

Signal peptide + **Human IL-15R alpha sushi** + *Linker variant 2* + **Human IL-15** + GS linker + Human IgG4 Fc + *GS linker X3* + **sPD-1 variant**

MAPRRARGCRTLGLPALLLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYIC  
NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSGQ  
NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIH  
DTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTSGGSGGG  
GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
GSGGGGSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFNTSESEFVLNWYR  
MSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCS  
AIVLAPKIQIKESLRVELRVTERRAEYPTAHPSPSRPAGQFOTLY

## FIGURE 28E

**Preprotein 9 including Signal Peptide 1 and Fusion protein 9 (SEQ ID NO: 46)**

Signal peptide + Human IL-15R alpha sushi + *Linker variant 3* + Human IL-15 + GS linker + Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MAPRRARGCRTLGLPALLLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLSRERYIC  
NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGSGGGSGGGSLQN  
WVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHD  
TVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTSGGSGGG  
GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
GSGGGGSGGGGSLDSPDRPWNPPTEFSPALLVYTEGDNATFTCSFNTSESEFVLNWYR  
MSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCS  
AIVLAPKIQIKESLRVELRVTERRAEYPTAHPSPSRPAGQFOTLY

**Preprotein 10 including Signal Peptide 1 and Fusion protein 10 (SEQ ID NO: 47)**

Signal peptide + Human IL-15R alpha sushi + *Linker variant 4* + Human IL-15 + GS linker + Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MAPRRARGCRTLGLPALLLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLSRERYIC  
NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGSGGGSGGGSLQN  
WVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHD  
TVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTSGGSGGG  
GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
GSGGGGSGGGGSLDSPDRPWNPPTEFSPALLVYTEGDNATFTCSFNTSESEFVLNWYR  
MSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCS  
AIVLAPKIQIKESLRVELRVTERRAEYPTAHPSPSRPAGQFOTLY

## FIGURE 28F

**Preprotein 11 including Signal Peptide 1 and Fusion protein 11 (SEQ ID NO: 48)**

Signal peptide + Human IL-15R alpha sushi + *Linker variant 5* + Human IL-15 + GS linker + Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MAPRRARGCRTLGLPALLLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLSRERYIC  
NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGSGGGSGGGSGGGSLQN  
WVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLES GDASIHD  
TVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTSGGSGGG  
GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
GSGGGSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFNTSESEFVLNWYR  
MSPSNQTDKLAAPEDRSOPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCS  
AIVLAPKIQIKESLRVELRVTERRAEYPTAHPSPSRPAGQFOTLY

**Preprotein 12 including Signal Peptide 1 and Fusion protein 12 (SEQ ID NO: 49)**

Signal peptide + Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15 + GS linker + Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MAPRRARGCRTLGLPALLLLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLSRERYIC  
NSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGSGGGSGGGSGGGSLQN  
WVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLES GDASIHD  
TVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVQMFINTSGGSGGG  
GSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN  
WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE  
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGG  
GSGGGSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFNTSESEFVLNWYR  
MSPSNQTDKLAAPEDRSOPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCS  
AIVLAPKIQIKESLRVELRVTERRAEYPTAHPSPSRPAGQFOTLY

## FIGURE 29A

**Preprotein 13 including Signal Peptide 2 and Fusion protein 1 (SEQ ID NO: 50)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 1* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSGQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECELEEKNKEFLQSFVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSDQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLSLGKSGGGGSGGGGS  
LDSPDRPWNPPTESPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAA  
FPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLY

**Preprotein 14 including Signal Peptide 2 and Fusion protein 2 (SEQ ID NO: 51)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 2* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSGQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECELEEKNKEFLQSFVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSDQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLSLGKSGGGGSGGGGS  
LDSPDRPWNPPTESPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAA  
FPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLY

## FIGURE 29B

**Preprotein 15 including Signal Peptide 2 and Fusion protein 3 (SEQ ID NO: 52)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 3* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLGLKSGGGGSGGGGS  
LDSPDRPWNPPTESPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAA  
FPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLY

**Preprotein 16 including Signal Peptide 2 and Fusion protein 4 (SEQ ID NO: 53)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 4* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLGLKSGGGGSGGGGS  
LDSPDRPWNPPTESPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAA  
FPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLY

## FIGURE 29C

**Preprotein 17 including Signal Peptide 2 and Fusion protein 5 (SEQ ID NO: 54)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 5* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGSGGGGSGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSDQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLSLGKSGGGGSGGGGS  
LDSPDRPWNPPTESPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAA  
FPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLY

**Preprotein 18 including Signal Peptide 2 and Fusion protein 6 (SEQ ID NO: 55)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGSGGGGSGSQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSDQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLSLGKSGGGGSGGGGS  
LDSPDRPWNPPTESPALLVYTEGDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAA  
FPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLY

## FIGURE 29D

**Preprotein 19 including Signal Peptide 2 and Fusion protein 7 (SEQ ID NO: 56)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 1* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSGQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKY  
GPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLSLGKSGGGGSGGGG  
GGGSLDSPDRPWNPPTESPALLYVTEGDNATFTCSFNTSESEFVLNWYRMSPSNQT  
DKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKI  
QIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

**Preprotein 20 including Signal Peptide 2 and Fusion protein 8 (SEQ ID NO: 57)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 2* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSGQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKY  
GPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLSLGKSGGGGSGGGG  
GGGSLDSPDRPWNPPTESPALLYVTEGDNATFTCSFNTSESEFVLNWYRMSPSNQT  
DKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKI  
QIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

## FIGURE 29E

**Preprotein 21 including Signal Peptide 2 and Fusion protein 9 (SEQ ID NO: 58)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 3* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGS  
GGGSLDSPDRPWNPPTESPALLYVTEGDNATFTCSFESNTSESEFVLNWYRMSPSNQT  
DKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKI  
QIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

**Preprotein 22 including Signal Peptide 2 and Fusion protein 10 (SEQ ID NO: 59)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 4* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGGSGGGGSGGGGSGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNSSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGS  
GGGSLDSPDRPWNPPTESPALLYVTEGDNATFTCSFESNTSESEFVLNWYRMSPSNQT  
DKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKI  
QIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

## FIGURE 29F

**Preprotein 23 including Signal Peptide 2 and Fusion protein 11 (SEQ ID NO: 60)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 5* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGSGGGSGGGSGGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLES GDASIHDTVENLII  
LANNSLSSNGNVTESGCKECEEELEEKNIKEFLOS FVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSDQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG  
SFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLGLKSGGGSGGGGS  
GGGSLDSPDRPWNPPTESPALLYVTEGDNATFTCSFESNTSESEFVLNWYRMSPSNQT  
DKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKI  
QIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

**Preprotein 24 including Signal Peptide 2 and Fusion protein 12 (SEQ ID NO: 61)**

Signal peptide 2 + Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15 + GS linker  
+ Human IgG4 Fc + *GS linker X3* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGSGGGSGGGSGGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLES GDASIHDTVENLII  
LANNSLSSNGNVTESGCKECEEELEEKNIKEFLOS FVHIVQMFINTSGGSGGGGSESKEYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPVTCVVVDVSDQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG  
SFFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLGLKSGGGSGGGGS  
GGGSLDSPDRPWNPPTESPALLYVTEGDNATFTCSFESNTSESEFVLNWYRMSPSNQT  
DKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKI  
QIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

## FIGURE 30A

## Fusion Protein 6A (SEQ ID NO: 62)

Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi + GS linker + Human IgG4 Fc  
+ GS linker X2 + sPD-1 variant

NWVNISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELOVISLESGDASIH  
DTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLOSFVHIVOMFINTSSGGGSG  
GGGSGGSGGGGSLQITCPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTE  
CVLNKAATNVAHWTTPSLKCIRGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKP  
KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS  
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVF  
SCSVMHREALHNHYTQKSLSLGLKSGGGGSGGGGSLDSPDRPWNPPTEFPALLVYTE  
GDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAAFPEDRSOPGQDCRFRVTQLPN  
GRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTAHPSPS  
PRPAGQFOTLY

## Fusion Protein 6B (SEQ ID NO: 63)

sPD-1 variant + GS linker X2 + Human IgG4 Fc + GS linker + Human IL-15 + Linker variant  
6 + Human IL-15R alpha sushi

LDSPDRPWNPPTEFPALLVVTEGDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAA  
FPEDRSOPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVTERRAEVPTAHPSPSPRPAGQFOTLYSGGGGSGGGGSESKYGPPCPPCPAPE  
FLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPR  
EEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTL  
PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLT  
VDKSRWQEGNVFSCSVMHREALHNHYTQKSLSLGLKGGSGGGGSNWVNISDLKKIE  
DLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELOVISLESGDASIHDTVENLIILANNSL  
SSNGNVTESGCKECEELEEKNIKEFLOSFVHIVOMFINTSSGGGSGGGGSGGSGGGGSL  
QITCPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKAATNVAHW  
TTPSLKCIR

## FIGURE 30B

## Fusion Protein 6C (SEQ ID NO: 64)

sPD-1 variant + *GS linker X2* + Human IgG4 Fc + *GS linker* + Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15

LDSPDRPWNPPTEFPALLVYTEGDNATFTCSFESNTSESFVLNWYRMSPSNQTDKLAA  
FPEDRSOPGODCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLYSGGGGSGGGGSESKYGPPCPPCPAPE  
FLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPR  
EEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTL  
PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLT  
VDKSRWQEGNVFSCSVMHEALHNHYTQKLSLSLGKGGSGGGGSTCPPPMSEHADI  
WVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTPSLKCISGGG  
GGGGSGGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFL  
LELOVISLESGDASIHDVTENLIILANNSLSSNGNVTESGCKECEEELEEKNIKEFLQSFVH  
IVQMFINTS

## Fusion Protein 6D (SEQ ID NO: 65)

Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15 + *GS linker X2* + sPD-1 variant + *GS linker* + Human IgG4 Fc

TCPPPMSEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTP  
PSLKCIRSGGGSGGGSGGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDVH  
PSCKVTAMKCFLLELOVISLESGDASIHDVTENLIILANNSLSSNGNVTESGCKECEEELE  
KNIKEFLQSFVHIVQMFINTSSGGGSGGGGSLDSPDRPWNPPTEFPALLVYTEGDNA  
TFTCSFESNTSESFVLNWYRMSPSNQTDKLAAFPEDRSOPGODCRFRVTQLPNGRDF  
HMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPSPRPA  
QFOTLYGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV  
VVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEY  
KCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV  
EWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYT  
QKLSLSLGK

## FIGURE 30C

## Fusion Protein 6E (SEQ ID NO: 66)

Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi + GS linker X2 + sPD-1 variant + GS linker + Human IgG4 Fc

NWVNISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIH  
DTVENLIILANNSLSSNGNVTESGCKECELEEKNIKEFLOSFVHIVOMFINTSSGGGSG  
GGGSGGSGGGGSLQTCPPPMSEHADIWVKSYSLSRERYICNSGFKRKAGTSSLTE  
CVLNKAATNAHWTTPSLKCIRSGGGGSGGGGSLDSPDRPWNPPTFSPALLYVTEGD  
NATFTCSFESNTSESFVLNWYRMSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGR  
DEHMSVVRARRNDSGTLYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTAHPSPSPR  
PAGQFOTLYGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTC  
VVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE  
YKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA  
VEWESNGQPENNYKTTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSYMHEALHNHY  
TQKSLSLSLGK

## Fusion Protein 6F (SEQ ID NO: 67)

sPD-1 variant + GS linker X2 + Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi + GS linker + Human IgG4 Fc

LDSPDRPWNPPTFSPALLYVTEGDNATFTCSFESNTSESFVLNWYRMSPSNQTDKLAAP  
EDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTLYLCSAIVLAPKIQIKESL  
RVELRVTERRAEVPTAHPSPSPRPAGQFOTLYSGGGGSGGGGSNWVNISDLKKIED  
LIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLIILANNSLS  
SNGNVTESGCKECELEEKNIKEFLOSFVHIVOMFINTSSGGGSGGGGSGGSGGGGSLQ  
TCPPPMSEHADIWVKSYSLSRERYICNSGFKRKAGTSSLTECVLNKAATNAHWTT  
PSLKCIRGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV  
VVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEY  
KCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV  
EWESNGQPENNYKTTPPVLDSDGSFELYSLRTVDKSRWQEGNVFSCSYMHEALHNHYT  
QKSLSLSLGK

## FIGURE 30D

## Fusion Protein 6G (SEQ ID NO: 68)

sPD-1 variant + GS linker X2 + Human IL-15R alpha sushi + Linker variant 6 + Human IL-15 + GS linker + Human IgG4 Fc

LDSPDRPWNPPTESPALLVYTEGDNATFTCSFESNTSESFVLNWYRMSPSNQTDKLA  
AFPEDRSQPGQDCRFRVTQLPNGRDEHMSVVRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLYSGGGSGGGGSTCPPPMSVEHADI  
WVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGG  
GGGGSGGGSGGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFL  
LELOVISLES GDASIHDTVENLIILANNSLSSNGNVTESGCKECEEELEEKNIKEFLOS FVH  
IVQMFINTSGGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV  
VVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEY  
KCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV  
EWESNGQPENNYKTTTPVLDS DGSEFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYT  
QKSLSLSLGK

## Fusion Protein 6H (SEQ ID NO: 69)

Human IgG4 Fc + GS linker + Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi  
 + GS linker X2 + sPD-1 variant

ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVVSQEDPEVQFNWY  
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS  
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTP  
VLDS DGSEFLYSRLTVDKSRWQEGNVFSCSYMHEALHNHYTQKSLSLSLGKGGSGGG  
GSNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELOVISLES GDAS  
IHDTVENLIILANNSLSSNGNVTESGCKECEEELEEKNIKEFLOS FVHIVQMFINTSGGG  
GGGGSGGGSGGGGSLQTCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLT  
ECVLNKA TNVAHWTTPSLKCIRSGGGSGGGGSLDSPDRPWNPPTESPALLVYTEG  
DNATFTCSFESNTSESFVLNWYRMSPSNQTDKLA AFPEDRSQPGQDCRFRVTQLPNG  
RDEHMSVVRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPSP  
RPAGQFOTLY

## FIGURE 30E

## Fusion Protein 6I (SEQ ID NO: 70)

Human IgG4 Fc + GS linker + Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15  
+ *GS linker X2* + sPD-1 variant

ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSOEDPEVQFNWY  
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS  
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTP  
VLDSGDSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKGGSGGG  
GSTCPPPMSEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAH  
WTTPSLKCIRSGGGSGGGSGGGSGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTES  
DVHPSCCKVTAMKCFLELQVISLESGLDASIHDTVENLIILANNSLSSNGNVTESGCKECE  
ELEEKNIKEFLQSFVHIVQMFINTSSGGGGSGGGGSLDSPDRPWNPTFESPALLYYTE  
GDNATFTCSFNTSESEFVLNWYRMSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPN  
GRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEYPTAHSPSP  
PRPAGQFOTLY

## Fusion Protein 6J (SEQ ID NO: 71)

Human IgG4 Fc + GS linker + sPD-1 variant + *GS linker X2* + Human IL-15 + *Linker variant*  
*6* + Human IL-15R alpha sushi

ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSOEDPEVQFNWY  
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS  
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTP  
VLDSGDSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKGGSGGG  
GSLDSPDRPWNPTFESPALLYVTEGDNATFTCSFNTSESEFVLNWYRMSPSNQTDKL  
AAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIK  
ESLRVELRVTERRAEYPTAHSPSPRPAGQFOTLYSGGGSGGGGSNWVNVISDLKKI  
EDLIQSMHIDATLYTESDVHPSCCKVTAMKCFLELQVISLESGLDASIHDTVENLIILANNS  
LSSNGNVTESGCKECELEEKNIKEFLQSFVHIVQMFINTSSGGGGSGGGSGGGSGGGGSL  
QTCPPPMSEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHW  
TTTPSLKCIR

## FIGURE 30F

## Fusion Protein 6K (SEQ ID NO: 72)

Human IgG4 Fc + GS linker + sPD-1 variant + GS linker X2 + Human IL-15R alpha sushi +  
Linker variant 6 + Human IL-15

ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSOEDPEVQFNWY  
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS  
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPP  
VLDSGDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKGGSGGG  
GSLDSPDRPWNPPTEFSPALLYVTEGDNATFTCSFESNTSESFVLNWYRMSPSNQTDKL  
AAFPEDRSQPGQDCRFRTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIK  
ESLRVELRVTERRAEVPTAHPSPSPRPAGQFQTLVSGGGGSGGGGSCPPPMSEHAD  
IWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGG  
GGGGSGGGSGGGGSLQNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFL  
LELQVISLES GDASIHDTVENLIILANNSLSSNGNVTESGCKECELEEKNIKEFLQSFVH  
IVQMFINTS

## FIGURE 31A

## Preprotein 18A (SEQ ID NO: 73)

Signal peptide 2 + Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi + GS linker + Human IgG4 Fc + GS linker X2 + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCK  
VTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEELEEKNIK  
EFLOSFVHIVOMFINTSSGGGSGGGGSGGGSGGGGSLQITCPPPMSVEHADIWVKSYSLY  
SRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTPSLKCIRGGSGGGGSESKYG  
PPCPPCPAPEFLGGPSVLEFPKPKDTLMISRTPVTCVVVDVSOEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGS  
LDSPDRPWNPPTEFPALLVYTEGDNATFTCSFSNTSESEFVLNWYRMSPSNQTDKLA  
AFPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARRNDSGTYLCSAIVLAPKIQIKESL  
RVELRVYTERRAEVPTAHPSPSPRPAGQFOTLY

## Preprotein 18B (SEQ ID NO: 74)

Signal peptide 2 + sPD-1 variant + GS linker X2 + Human IgG4 Fc + GS linker + Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi

MDMRVPAQLLGLLLLWLRGARCLDSPDRPWNPPTEFPALLVYTEGDNATFTCSFSNT  
SESEFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVYRARR  
RNDSGTYLCSAIVLAPKIQIKESLRVELRVYTERRAEVPTAHPSPSPRPAGQFOTLYSG  
GGGSGGGGSESKYGPCCPPCPAPEFLGGPSVLEFPKPKDTLMISRTPVTCVVVDVSOE  
DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSN  
KGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG  
QPENNYKTTPVLDSGDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSL  
LGLKGGSGGGGSNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLEL  
QVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEEELEEKNIKEFLOSFVHIV  
OMFINTSSGGGSGGGGSGGGSGGGGSLQITCPPPMSVEHADIWVKSYSLYSRERYICNSG  
KRKAGTSSLTECVLNKATNVAHWTPSLKCIR

## FIGURE 31B

## Preprotein 18C (SEQ ID NO: 75)

Signal peptide 2 + sPD-1 variant + GS linker X2 + Human IgG4 Fc + GS linker + Human IL-15R alpha sushi + Linker variant 6 + Human IL-15

MDMRVPAQLLGLLLLWLRGARCLDSPDRPWNPPTEFPALLVVTEGDNATFTCSFESNT  
SESEFVLNWYRMSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRAR  
RNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLVSG  
GGGSGGGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ  
DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSN  
KGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG  
QPENNYKTTTPVLDSGDGSFFLYSRLTVDKSRWQEGNVFSCSVMHREALHNHYTQKSLSL  
LGKGGSGGGGSTCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECV  
LNKATNVAHWTTTPSLKCIRSGGGSGGGGSGGGSGGGSLQNWVNVISDLKKIEDLIQSM  
HIDATLYTESDVHPSCKVTAMKCFLELOVISLES GDASIHDTVENLIILANNSLSSNGNV  
TESGCKECEEELEEKNIKEFLOS FVHIVQMFINTS

## Preprotein 18D (SEQ ID NO: 76)

Signal peptide 2 + Human IL-15R alpha sushi + Linker variant 6 + Human IL-15 + GS linker X2 + sPD-1 variant + GS linker + Human IgG4 Fc

MDMRVPAQLLGLLLLWLRGARCTCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTTPSLKCIRSGGGSGGGGSGGGSGGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLES GDASIHDTVENLI  
LANNSLSSNGNVTESGCKECEEELEEKNIKEFLOS FVHIVQMFINTSSGGGGSGGGGSLD  
SPDRPWNPPTEFPALLVVTEGDNATFTCSFESNTSESEFVLNWYRMSPSNQTDKLAAP  
EDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSTYLC  
SAIVLAPKIQIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLVGGSGGGGSESKYGPPCPPCPAPEFLGG  
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQ  
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ  
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDGSFFLYSRLTVDK  
SRWQEGNVFSCSVMHREALHNHYTQKSLSLSLGK

## FIGURE 31C

## Preprotein 18E (SEQ ID NO: 77)

Signal peptide 2 + Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi + GS linker X2 + sPD-1 variant + GS linker + Human IgG4 Fc

MDMRVPAQLLGLLLLWLRGARCNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCK  
VTAMKCFLELOVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECELEEKNIK  
EFLOSFVHIVOMFINTSSGGGSGGGGSGGSGGGGSLQTCPPPMSEHADIWVKSYSLY  
SRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTPSLKCIRSGGGGSGGGGSLDS  
PDRPWNPTFESPALLVYTEGDNATFTCSFSNTSESEVLNWYRMSPSNQTDKLAAFPE  
DRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSTYLCSAIVLAPKIQIKESLRV  
ELRVTERRAEVPTAHPSPPRPAGQFQTLVGGSGGGGSESKYGPPCPPCPAPEFLGGP  
SVLEFPKPKDTLMISRTPEVTCVVVDVSOEDPEVQFNWYVDGVEVHNAKTKPREEQFN  
STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQE  
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKS  
RWQEGNVFSCSVMEALHNHYTQKSLSLGLGK

## Preprotein 18F (SEQ ID NO: 78)

Signal peptide 2 + sPD-1 variant + GS linker X2 + Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi + GS linker + Human IgG4 Fc

MDMRVPAQLLGLLLLWLRGARCLDSPDRPWNPTFESPALLVYTEGDNATFTCSFSNT  
SESEVLNWYRMSPSNQTDKLAAEPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRAR  
RNDSTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTAHPSPPRPAGQFQTLVSG  
GGGSGGGGSNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVIS  
LESGDASIHDTVENLIILANNSLSSNGNVTESGCKECELEEKNIKEFLOSFVHIVOMFI  
NTSSGGGSGGGGSGGSGGGGSLQTCPPPMSEHADIWVKSYSLSRERYICNSGFKRK  
AGTSSLTECVLNKATNVAHWTPSLKCIRGGSGGGGSESKYGPPCPPCPAPEFLGGPS  
VFLEFPKPKDTLMISRTPEVTCVVVDVSOEDPEVQFNWYVDGVEVHNAKTKPREEQENS  
TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE  
MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSR  
WQEGNVFSCSVMEALHNHYTQKSLSLGLGK

## FIGURE 31D

## Preprotein 18G (SEQ ID NO: 79)

Signal peptide 2 + sPD-1 variant + GS linker X2 + Human IL-15R alpha sushi + Linker variant 6 + Human IL-15 + GS linker + Human IgG4 Fc

MDMRVPAQLLGLLLLWLRGARCLDSPDRPWNPPTESPALLVYTEGDNATFTCSSENT  
 SESFVLNWYRMSPSNQTDKLAAPEDRSOPGQDCRERVLTQLPNGRDFHMSVVRAR  
 RNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFOTLVSG  
 GGGSGGGSTCPPPMSVEHADIWVKSYSLSRERYICNSGFKRKAGTSSLTECVLNK  
 ATNVAHWTTPSLKCIRSGGGSGGGSGGGSGGGSLQNWVNVISDLKKIEDLIQSMHID  
 ATLYTESDVHPSCKVTAMKCFLELQVISLES GDASIHDTVENLIILANNSLSSNGNVTES  
 GCKECEELEEKNIKEFLOS FVHIVQMFINTSSGGSGGGGSESKYGPPCPPCPAPEFLGGPS  
 VFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS  
 TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE  
 MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSR  
 WQEGNVFSCSVMHREALHNHYTQKSLSLSLGK

## Preprotein 18H (SEQ ID NO: 80)

Signal peptide 2 + Human IgG4 Fc + GS linker + Human IL-15 + Linker variant 6 + Human IL-15R alpha sushi + GS linker X2 + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRT  
 PEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW  
 LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGF  
 YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA  
 LHNHYTQKSLSLSLGKGGSGGGGSNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSC  
 KVTAMKCFLELQVISLES GDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNI  
 KEFLOS FVHIVQMFINTSSGGSGGGGSLQTCPPPMSVEHADIWVKSYSLSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGSGGGGSL  
 DSPDRPWNPPTESPALLVYTEGDNATFTCSSENTSESEFVLNWYRMSPSNQTDKLAAP  
 PEDRSOPGQDCRERVLTQLPNGRDFHMSVVRARRRNDSTYLCASIVLAPKIQIKESL  
 RVELRVTERRAEVPTAHPSPSPRPAGQFOTLV

## FIGURE 31E

**Preprotein 18I (SEQ ID NO: 81)**

Signal peptide 2 + Human IgG4 Fc + GS linker + Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15 + GS linker X2 + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRT  
 PEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW  
 LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGF  
 YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA  
 LHNHYTQKSLSLSLGKGGSGGGGSGTCTPPPMSEHADIWVKSYSLYSRERYICNSGFK  
 RKAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGGSGGGSGGGSGGGGSLQNWVNV  
 SDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELQVISLESGDASIHDTVENLI  
 ILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTSSGGGGSGGGGSLD  
 SPDRPWNPTFESPALLVYTEGDNATFTCSFSNTSESEFVLNWYRMSPSNQTDKLAAP  
 EDRSQPGQDCRFRVTQLPNGRDFHMSYVRARRNDSGTYLCSAIVLAPKIQIKESLR  
 VELRVTERRAEYPTAHPSPSPRPAQGFOTLV

**Preprotein 18J (SEQ ID NO: 82)**

Signal peptide 2 + Human IgG4 Fc + GS linker + sPD-1 variant + GS linker X2 + Human IL-15 + *Linker variant 6* + Human IL-15R alpha sushi

MDMRVPAQLLGLLLLWLRGARCESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRT  
 PEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW  
 LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGF  
 YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA  
 LHNHYTQKSLSLSLGKGGSGGGGSLDSPDRPWNPTFESPALLVYTEGDNATFTCSFS  
 NTSESEFVLNWYRMSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMSYVR  
 ARRNDSGTYLCSAIVLAPKIQIKESLRVELRVTERRAEYPTAHPSPSPRPAQGFOTLV  
 VSGGGSGGGGSNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLEL  
 QVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQ  
 MFINTSSGGGGSGGGSGGGSGGGGSLQTCPPPMSEHADIWVKSYSLYSRERYICNSGF  
 KRKAGTSSLTECVLNKATNVAHWTTPSLKCIR

## FIGURE 31F

## Preprotein 18K (SEQ ID NO: 83)

Signal peptide 2 + Human IgG4 Fc + GS linker + sPD-1 variant + *GS linker X2* + Human IL-15R alpha sushi + *Linker variant 6* + Human IL-15

MDMRVPAQLLGLLLLWLRGARCESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRT  
PEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHODW  
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGF  
YPSDIAVEWESNGQPENNYKTTTPVLDSGSEFLYSRLTVDKSRWQEGNVFSCSVMHEA  
LHNHYTQKSLSLGLKGGSGGGGSLDSPDRPWNPTFSPALLVYTEGDNATFTCSFS  
NTSESFVLNWMSPSNQTDKLAAPEDRSQPGQDCRFRTQLPNGRDFHMSVVR  
ARRNDSTYLCSAIVLAPKIQIKESLRVELRVTERRAEVPTAHPSPSPRPAGQFQTL  
VSGGGGSGGGGSCPPPMSEHADIWVKSYSLSRERYICNSGFKRKAGTSSLTECVL  
NKATNVAHWTTPSLKCISSGGGSGGGGSGGSGGGGSLQNWVNVISDLKKIEDLIQSMH  
IDATLYTESDVHPSCKVTAMKCFLELQVISLESGLDASIHDTVENLIILANNSLSSNGNVT  
ESGCKECEELEEKNIKEFLOSFEVHIVQMFINTS

## FIGURE 32A

DNA sequence encoding preprotein 1 (SEQ ID NO: 84)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 1 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X2 + sPD-1 variant + Stop Codon.

GCCACCATGGCTCCTCGTAGAGCTAGAGGCTGTAGAACCCTGGGACTGCCTGCTCTG  
CTGCTGTTGTTGCTGCTCAGACCTCCTGCCACCAGAGGCATCACATGCCCTCCACCT  
ATGTCCGTGGAACACGCCGACATCTGGGTCAAGTCTTACAGCCTGTACTCCAGA  
GAGCGGTACATCTGCAACTCCGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCT  
GACCGAGTGCGTGCTGAACAAGGCCACCAATGTGGCCCACTGGACCACACCTA  
GCCTGAAGTGCATCAGATCCGGTGGTGGAGGTAGCGGGGGCGGTGGATCAGGAGGA  
GGGAGTGGGGGAAGTGGCCAAATTGGGTCAACGTGATCTCCGACCTGAAGAAGATCG  
AGGACCTGATCCAGTCCATGCACATCGACGCTACCCTGTACACCGAGTCCGACGTGCA  
CCCTTCCTGTAAAGTGACCGCCATGAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCC  
CTGGAATCCGGCGACGCCTCTATCCACGACACCGTGGAACCTGATCATCCTGGCCA  
ACAACCTCCCTGTCCTCCAACGGCAACGTGACCGAGTCTGGCTGCAAGAGTGGAGG  
AACTGGAAGAGAAGAACATCAAAGAGTTCCTCCAGTCTTCGTGCACATCGTGCGAGAT  
GTTTCATCAACACCTCCGGCGGAAGTGGTGGTGGCGGCTCTGAGTCTAAGTACGGC  
CCTCCTTGTCACCTTGTCCTGCTCCAGAGTTTCTCGGCGGACCCCTCCGTGTTCTCTGT  
TTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCG  
TGGTGGTTCGATGTGTCCCAAGAGGATCCCGAGGTGCAGTTCAATTGGTACGTGGACG  
GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTTCAACTCCACC  
TACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGA  
GTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTC  
CAAGGCCAAGGGCCAGCCTAGGGAACCCAGGTTTACACCCTGCCTCCAAGCCAAG  
AGGAAATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTT  
CCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACCTACAAGACA  
ACCCCTCCTGTGCTGGACTCCGACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGG  
ACAAGTCCAGATGGCAAGAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCC  
TGCACAATCACTACCCAGAAAGTCCCTGTCTCTGTCCCTGGGCAAAAGTGGCGGAG  
GTGGAAGCGGTGGCGGTGGAAGTTTGGACTCTCCTGACAGACCTTGGAACCTCC  
AACCTTCTCTCCCGCTCTGCTGGTGGTTACCGAGGGCGACAATGCCACCTTCAC  
CTGTTCCCTCAGCAACACCAGCGAGTCCTTTGTGCTGAACTGGTACAGAATGTC  
CCCTAGCAACCAGACCGACAAGCTGGCCGCCTTTCCTGAGGACAGATCTCAGC  
CAGGCCAGGACTGCCGGTTCAGAGTTACCCAGCTGCCTAACGGCCGGGACTTC  
CACATGTCTGTGCTGCGGGCCAGAAGAAACGACTCTGGCACCTACCTGTGCTC  
CGCTATTGTGCTGGCCCCTAAGATCCAGATCAAAGAGAGCCTGCGGGTTCGAGCT  
GAGAGTGACAGAGCGTAGAGCTGAAGTGCCACCGCTCATCCCTCACCTTCTC  
CAAGACCTGCCGGCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 32B

DNA sequence encoding preprotein 2 (SEQ ID NO: 85)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 2 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X2 + sPD-1 variant + Stop Codon.

GCCACCATGGCTCCTCGTAGAGCTAGAGGCTGTAGAACCCTGGGACTGCCTGCTCTG  
CTGCTGTTGTTGCTGCTCAGACCTCCTGCCACCAGAGGCATCACATGCCCTCCACCT  
ATGTCCGTGGAACACGCCGACATCTGGGTCAAGTCTTACAGCCTGTACTCCAGA  
GAGCGGTACATCTGCAACTCCGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCT  
GACCGAGTGCGTGCTGAACAAGGCCACCAATGTGGCCCACTGGACCACACCTA  
GCCTGAAGTGCATCAGATCTGGGGGGGGTGGGTGAGGTGGTGGGAGTGGCGGAGGT  
GGATCAGGTGGATCCGGTCAAAATTGGGTCAACGTGATCTCCGACCTGAAGAAGATCG  
AGGACCTGATCCAGTCCATGCACATCGACGCTACCCTGTACACCGAGTCCGACGTGCA  
CCCTTCCTGTAAAGTGACCGCCATGAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCC  
CTGGAATCCGGCGACGCCTCTATCCACGACACCGTGGAACCTGATCATCCTGGCCA  
ACAACCTCCCTGTCCTCCAACGGCAACGTGACCGAGTCTGGCTGCAAGAGTGCGAGG  
AACTGGAAGAGAAGAACATCAAAGAGTTCCTCCAGTCTTCGTGCACATCGTGAGAT  
GTTTCATCAACACCTCCGGCGGAAGTGGTGGTGGCGGCTCTGAGTCTAAGTACGGC  
CCTCCTTGTCACCTTGTCCTGCTCCAGAGTTTCTCGGCGGACCCCTCCGTGTTCTCTG  
TTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCG  
TGGTGGTTCGATGTGTCCCAAGAGGATCCCGAGGTGCAGTTCAATTGGTACGTGGACG  
GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTTCAACTCCACC  
TACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGA  
GTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTC  
CAAGGCCAAGGGCCAGCCTAGGGAACCCAGGTTTACACCCTGCCTCCAAGCCAAG  
AGGAAATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTT  
CCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACCTACAAGACA  
ACCCCTCCTGTGCTGGACTCCGACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGG  
ACAAGTCCAGATGGCAAGAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCC  
TGCACAATCACTACCCAGAAGTCCCTGTCTCTGTCCCTGGGCAAAAGTGGCGGAG  
GTGGAAGCGGTGGCGGTGGAAGTTTGGACTCTCCTGACAGACCTTGGAACCTCC  
AACCTTCTCTCCCGCTCTGCTGGTGGTTACCGAGGGCGACAATGCCACCTTCAC  
CTGTTCCCTCAGCAACACCAGCGAGTCCTTTGTGCTGAACTGGTACAGAATGTC  
CCCTAGCAACCAGACCGACAAGCTGGCCGCCTTTCCTGAGGACAGATCTCAGC  
CAGGCCAGGACTGCCGGTTCAGAGTTACCCAGCTGCCTAACGGCCGGGACTTC  
CACATGTCTGTGCTGCGGGCCAGAAGAAACGACTCTGGCACCTACCTGTGCTC  
CGCTATTGTGCTGGCCCCTAAGATCCAGATCAAAGAGAGCCTGCGGGTTCGAGCT  
GAGAGTGACAGAGCGTAGAGCTGAAGTGCCACCGCTCATCCCTCACCTTCTC  
CAAGACCTGCCGGCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 32C

DNA sequence encoding preprotein 3 (SEQ ID NO: 86)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 3 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X2 + sPD-1 variant + Stop Codon.

GCCACCATGGCTCCTCGTAGAGCTAGAGGCTGTAGAACCCTGGGACTGCCTGCTCTG  
CTGCTGTTGTTGCTGCTCAGACCTCCTGCCACCAGAGGCATCACATGCCCTCCACCT  
ATGTCCGTGGAACACGCCGACATCTGGGTCAAGTCTTACAGCCTGTACTCCAGA  
GAGCGGTACATCTGCAACTCCGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCT  
GACCGAGTGCGTGCTGAACAAGGCCACCAATGTGGCCCACTGGACCACACCTA  
GCCTGAAGTGCATCAGATCTGGCGGAGGAGGAAGTGGCGGTAGCGGAGGTAGCGGT  
GGAGGCGGTAGTGGCTCACAATAATTGGGTCAACGTGATCTCCGACCTGAAGAAGATCG  
AGGACCTGATCCAGTCCATGCACATCGACGCTACCCTGTACACCGAGTCCGACGTGCA  
CCCTTCCTGTAAAGTGACCGCCATGAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCC  
CTGGAATCCGGCGACGCCTCTATCCACGACACCGTGGAACCTGATCATCCTGGCCA  
ACAACCTCCCTGTCCTCCAACGGCAACGTGACCGAGTCTGGCTGCAAGAGTGCGAGG  
AACTGGAAGAGAAGAACATCAAAGAGTTCCTCCAGTCTTCGTGCACATCGTGAGAT  
GTTTCATCAACACCTCCGGCGGAAGTGGTGGTGGCGGCTCTGAGTCTAAGTACGGC  
CCTCCTTGTCACCTTGTCCTGCTCCAGAGTTTCTCGGCGGACCCTCCGTGTTCTCTGT  
TTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCG  
TGGTGGTTCGATGTGTCCCAAGAGGATCCCGAGGTGCAGTTCAATTGGTACGTGGACG  
GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTTCAACTCCACC  
TACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGA  
GTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTC  
CAAGGCCAAGGGCCAGCCTAGGGAACCCAGGTTTACACCCTGCCTCCAAGCCAAG  
AGGAAATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTT  
CCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACCTACAAGACA  
ACCCCTCCTGTGCTGGACTCCGACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGG  
ACAAGTCCAGATGGCAAGAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCC  
TGCACAATCACTACCCAGAAAGTCCCTGTCTCTGTCCCTGGGCAAAAGTGGCGGAG  
GTGGAAGCGGTGGCGGTGGAAGTTTGGACTCTCCTGACAGACCTTGGAACCTCC  
AACCTTCTCTCCCGCTCTGCTGGTGGTTACCGAGGGCGACAATGCCACCTTCAC  
CTGTTCCCTCAGCAACACCAGCGAGTCCTTTGTGCTGAACTGGTACAGAATGTC  
CCCTAGCAACCAGACCGACAAGCTGGCCGCCTTTCTGAGGACAGATCTCAGC  
CAGGCCAGGACTGCCGGTTCAGAGTTACCCAGCTGCCTAACGGCCGGGACTTC  
CACATGTCTGTGCTGCGGGCCAGAAGAAACGACTCTGGCACCTACCTGTGCTC  
CGCTATTGTGCTGGCCCCTAAGATCCAGATCAAAGAGAGCCTGCGGGTTCGAGCT  
GAGAGTGACAGAGCGTAGAGCTGAAGTGCCACCGCTCATCCCTCACCTTCTC  
CAAGACCTGCCGGCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 32D

DNA sequence encoding preprotein 7 (SEQ ID NO: 87)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 1 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X3 + sPD-1 variant + Stop Codon.

GCCACCATGGCTCCTCGTAGAGCTAGAGGCTGTAGAACCCTGGGACTGCCTGCTCTG  
CTGCTGTTGTTGCTGCTCAGACCTCCTGCCACCAGAGGCATCACATGCCCTCCACCT  
ATGTCCGTGGAACACGCCGACATCTGGGTCAAGTCTTACAGCCTGTACTCCAGA  
GAGCGGTACATCTGCAACTCCGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCT  
GACCGAGTGCGTGCTGAACAAGGCCACCAATGTGGCCCACTGGACCACACCTA  
GCCTGAAGTGCATCAGATCCGGTGGTGGAGGTAGCGGGGGCGGTGGATCAGGAGGA  
GGGAGTGGGGGAAGTGGCCAAATTGGGTCAACGTGATCTCCGACCTGAAGAAGATCG  
AGGACCTGATCCAGTCCATGCACATCGACGCTACCCTGTACACCGAGTCCGACGTGCA  
CCCTTCCTGTAAAGTGACCGCCATGAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCC  
CTGGAATCCGGCGACGCCTCTATCCACGACACCGTGGAACCTGATCATCCTGGCCA  
ACAACCTCCCTGTCCTCCAACGGCAACGTGACCGAGTCTGGCTGCAAGAGTGCGAGG  
AACTGGAAGAGAAGAACATCAAAGAGTTCCTCCAGTCTTCGTGCACATCGTGAGAT  
GTTTCATCAACACCTCCGGCGGAAGTGGTGGTGGCGGCTCTGAGTCTAAGTACGGC  
CCTCCTTGTCACCTTGTCCTGCTCCAGAGTTTCTCGGCGGACCTCCGTGTTCTCTGT  
TTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCG  
TGGTGGTTCGATGTGTCCCAAGAGGATCCCGAGGTGCAGTTCAATTGGTACGTGGACG  
GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTTCAACTCCACC  
TACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGA  
GTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTC  
CAAGGCCAAGGGCCAGCCTAGGGAACCCAGGTTTACACCCTGCCTCCAAGCCAAG  
AGGAAATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTT  
CCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACCTACAAGACA  
ACCCCTCCTGTGCTGGACTCCGACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGG  
ACAAGTCCAGATGGCAAGAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCC  
TGCACAATCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGCAAAAGTGGCGGAG  
GTGGAAGCGGTGGCGGTGGTTCAGGTGGCGGCGGTAGTTTGGACTCTCCTGACAGA  
CCTTGGAACCTCCAACCTTCTCTCCCGCTCTGCTGGTGGTTACCGAGGGCGAC  
AATGCCACCTTCACCTGTTCTTCAGCAACACCAGCGAGTCCTTTGTGCTGAAC  
TGGTACAGAATGTCCCCTAGCAACCAGACCGACAAGCTGGCCGCCTTTCTCTGAG  
GACAGATCTCAGCCAGGCCAGGACTGCCGGTTCAGAGTTACCCAGCTGCCTAA  
CGGCCGGGACTTCCACATGTCTGTCTGTCGGGCCAGAAGAAACGACTCTGGCA  
CCTACCTGTGCTCCGCTATTGTGCTGGCCCCCTAAGATCCAGATCAAAGAGAGCC  
TGCGGGTTCGAGCTGAGAGTGACAGAGCGTAGAGCTGAAGTGCCACCGCTCAT  
CCCTCACCTTCTCCAAGACCTGCCGGCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 32E

DNA sequence encoding preprotein 8 (SEQ ID NO: 88)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 2 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X3 + sPD-1 variant + Stop Codon.

GCCACCATGGCTCCTCGTAGAGCTAGAGGCTGTAGAACCCTGGGACTGCCTGCTCTG  
CTGCTGTTGTTGCTGCTCAGACCTCCTGCCACCAGAGGCATCACATGCCCTCCACCT  
ATGTCCGTGGAACACGCCGACATCTGGGTCAAGTCTTACAGCCTGTACTCCAGA  
GAGCGGTACATCTGCAACTCCGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCT  
GACCGAGTGCGTGCTGAACAAGGCCACCAATGTGGCCCACTGGACCACACCTA  
GCCTGAAGTGCATCAGATCTGGGGGGGGGTGGGTGAGGTGGTGGGAGTGGCGGAGGT  
GGATCAGGTGGATCCGGTCAAAATTGGGTCAACGTGATCTCCGACCTGAAGAAGATCG  
AGGACCTGATCCAGTCCATGCACATCGACGCTACCCTGTACACCGAGTCCGACGTGCA  
CCCTTCCTGTAAAGTGACCGCCATGAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCC  
CTGGAATCCGGCGACGCCTCTATCCACGACACCGTGGAACCTGATCATCCTGGCCA  
ACAACCTCCCTGTCCTCCAACGGCAACGTGACCGAGTCTGGCTGCAAGAGTGGGAGG  
AACTGGAAGAGAAGAACATCAAAGAGTTCCTCCAGTCTTCGTGCACATCGTGAGAT  
GTTTCATCAACACCTCCGGCGGAAGTGGTGGTGGCGGCTCTGAGTCTAAGTACGGC  
CCTCCTTGTCACCTTGTCCTGCTCCAGAGTTTCTCGGCGGACCCCTCCGTGTTCTCTG  
TTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCG  
TGGTGGTTCGATGTGTCCCAAGAGGATCCCGAGGTGCAGTTCAATTGGTACGTGGACG  
GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTTCAACTCCACC  
TACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGA  
GTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTC  
CAAGGCCAAGGGCCAGCCTAGGGAACCCAGGTTTACACCCTGCCTCCAAGCCAAG  
AGGAAATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTT  
CCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACCTACAAGACA  
ACCCCTCCTGTGCTGGACTCCGACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGG  
ACAAGTCCAGATGGCAAGAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCC  
TGCACAATCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGCAAAAGTGGCGGAG  
GTGGAAGCGGTGGCGGTGGTTCAGGTGGCGGCGGTAGTTTGGACTCTCCTGACAGA  
CCTTGGAACCTCCAACCTTCTCTCCCGCTCTGCTGGTGGTTACCGAGGGCGAC  
AATGCCACCTTCACCTGTTCTTCAGCAACACCAGCGAGTCCTTTGTGCTGAAC  
TGGTACAGAATGTCCCCTAGCAACCAGACCGACAAGCTGGCCGCCTTTCCTGAG  
GACAGATCTCAGCCAGGCCAGGACTGCCGGTTCAGAGTTACCCAGCTGCCTAA  
CGGCCGGGACTTCCACATGTCTGTCTGCGGGGCCAGAAGAAACGACTCTGGCA  
CCTACCTGTGCTCCGCTATTGTGCTGGCCCTAAGATCCAGATCAAAGAGAGCC  
TGCGGGTTCGAGCTGAGAGTGACAGAGCGTAGAGCTGAAGTGCCACCGCTCAT  
CCCTCACCTTCTCCAAGACCTGCCGGCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 32F

DNA sequence encoding preprotein 9 (SEQ ID NO: 89)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 3 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X3 + sPD-1 variant + Stop Codon.

GCCACCATGGCTCCTCGTAGAGCTAGAGGCTGTAGAACCCTGGGACTGCCTGCTCTG  
CTGCTGTTGTTGCTGCTCAGACCTCCTGCCACCAGAGGCATCACATGCCCTCCACCT  
ATGTCCGTGGAACACGCCGACATCTGGGTCAAGTCTTACAGCCTGTACTCCAGA  
GAGCGGTACATCTGCAACTCCGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCT  
GACCGAGTGCGTGCTGAACAAGGCCACCAATGTGGCCCACTGGACCACACCTA  
GCCTGAAGTGCATCAGATCTGGCGGAGGAGGAAGTGGCGGTAGCGGAGGTAGCGGT  
GGAGGCGGTAGTGGCTCACAATAATTGGGTCAACGTGATCTCCGACCTGAAGAAGATCG  
AGGACCTGATCCAGTCCATGCACATCGACGCTACCCTGTACACCGAGTCCGACGTGCA  
CCCTTCCTGTAAAGTGACCGCCATGAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCC  
CTGGAATCCGGCGACGCCTCTATCCACGACACCGTGGAACCTGATCATCCTGGCCA  
ACAACCTCCCTGTCCTCCAACGGCAACGTGACCGAGTCTGGCTGCAAGAGTGCGAGG  
AACTGGAAGAGAAGAACATCAAAGAGTTCCTCCAGTCTTCGTGCACATCGTGAGAT  
GTTTCATCAACACCTCCGGCGGAAGTGGTGGTGGCGGCTCTGAGTCTAAGTACGGC  
CCTCCTTGTCACCTTGTCCTGCTCCAGAGTTTCTCGGCGGACCCCTCCGTGTTCTCTG  
TTCCTCCAAAGCCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCG  
TGGTGGTTCGATGTGTCCCAAGAGGATCCCGAGGTGCAGTTCAATTGGTACGTGGACG  
GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTTCAACTCCACC  
TACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGA  
GTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTC  
CAAGGCCAAGGGCCAGCCTAGGGAACCCAGGTTTACACCCTGCCTCCAAGCCAAG  
AGGAAATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTT  
CCGATATCGCCGTGGAATGGGAGAGCAATGGCCAGCCTGAGAACAACCTACAAGACA  
ACCCCTCCTGTGCTGGACTCCGACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGG  
ACAAGTCCAGATGGCAAGAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCC  
TGCACAATCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGCAAAAGTGGCGGAG  
GTGGAAGCGGTGGCGGTGGTTCAGGTGGCGGCGGTAGTTTGGACTCTCCTGACAGA  
CCTTGGAACCTCCAACCTTCTCTCCCGCTCTGCTGGTGGTTACCGAGGGCGAC  
AATGCCACCTTCACCTGTTCTTCAGCAACACCAGCGAGTCCTTTGTGCTGAAC  
TGGTACAGAATGTCCCCTAGCAACCAGACCGACAAGCTGGCCGCCTTTCTCTGAG  
GACAGATCTCAGCCAGGCCAGGACTGCCGGTTCAGAGTTACCCAGCTGCCTAA  
CGGCCGGGACTTCCACATGTCTGTCTGCGGGCCAGAAGAAACGACTCTGGCA  
CCTACCTGTGCTCCGCTATTGTGCTGGCCCTAAGATCCAGATCAAAGAGAGCC  
TGCGGGTTCGAGCTGAGAGTGACAGAGCGTAGAGCTGAAGTGCCACCGCTCAT  
CCCTCACCTTCTCCAAGACCTGCCGGCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 32G

DNA sequence encoding preprotein 13 (SEQ ID NO: 90)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 1 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X2 + sPD-1 variant + Stop Codon.

GCCACCATGGACATGAGAGTGCCTGCTCAGCTGCTGGGACTGCTGCTGTTGTGGTTG  
AGAGGCGCCAGATGCATCACCTGTCTCCACCTATGTCCGTGGAACACGCCGAC  
ATCTGGGTCAAGTCTACAGCCTGTACTCCAGAGAGCGGTACATCTGCAACTCC  
GGCTTCAAGAGAAAAGGCCGGCACCTCTAGCCTGACCGAGTGCGTGCTGAACAA  
GGCCACCAATGTGGCCCACTGGACCACACCTAGCCTGAAGTGCATCAGATCCGG  
TGGTGGAGGTAGCGGGGGCGGTGGATCAGGAGGAGGGAGTGGGGGAAGTGGCCAAAAT  
TGGGTCAACGTGATCTCCGACCTGAAGAAGATCGAGGACCTGATCCAGTCCATGCACA  
TCGACGCTACCTGTACACCGAGTCCGACGTGCACCCTTCCTGTAAAGTGACCGCCAT  
GAAGTGCTTTCTGCTGGAAGTGCAAGTGATCTCCCTGGAATCCGGCGACGCCTCTATC  
CACGACACCGTGGAACCTGATCATCTGGCCAACAACCTCCCTGTCCAGCAACGGCA  
ACGTGACCGAGTCTGGCTGCAAGAGTGCGAGGAACTGGAAGAGAAGAACATCAAAG  
AGTTCTCCAGTCTTCGTGCACATCGTGAGATGTTTCATCAACACCTCCGGCGGATC  
TGGTGGCGGTGGATCCGAGTCTAAGTACGGCCCTCCTTGTCCTCCATGTCTCTGCTCC  
AGAGTTTCTCGGCGGACCCTCCGTGTTCTCTGTTTCTCCAAAGCCTAAGGACACCCT  
GATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTTCGATGTGTCCCAAGAGGA  
TCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACAACGCCAAGA  
CCAAGCCTAGAGAGGAACAGTTCAACTCCACCTACAGAGTGGTGTCCGTGCTGACCG  
TGCTGCACCAAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG  
GGCCTGCCTTCCAGCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTAGGGA  
ACCCAGGTTTACACCCTGCCTCCAAGCCAAGAGGAAATGACCAAGAACCAGGTGT  
CCCTGACCTGCCTGGTCAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGGAGAG  
CAATGGCCAGCCTGAGAACAACTACAAGACAACCCCTCCTGTGCTGGACTCCGACGG  
CTCCTTCTTTCTGTACTCCCGCCTGACCGTGGACAAGTCCAGATGGCAAGAGGGCAA  
CGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGTC  
CCTGTCTCTGTCCCTGGGCAAATCTGGCGGAGGTGGAAGTGGCGGTGGCGGATCTTT  
GGACTCTCCTGACAGACCTTGGAACCCTCCAACCTTCTCTCCCGCTCTGCTGGT  
GGTTACCGAGGGCGACAATGCCACCTTCACCTGTTCTTCAGCAACACCAGCGA  
GTCTTTGTGCTGAACTGGTACAGAATGTCCCCTAGCAACCAGACCGACAAGCT  
GGCCGCCTTTCCTGAGGACAGATCTCAGCCAGGCCAGGACTGCCGGTTCAGAG  
TTACCCAGCTGCCTAACGGCCGGGACTTCCACATGTCTGTCTGTCGGGGCCAGA  
AGAAACGACTCTGGCACCTACCTGTGCTCCGCTATTGTGCTGGCCCTAAGATC  
CAGATCAAAGAGAGCCTGCGGGTCGAGCTGAGAGTGACAGAGCGTAGAGCTGA  
GGTGCCACCGCTCATCTTCACCTTCTCCAAGACCTGCCGGCCAGTTTCAGAC  
CCTCGTGTGATAA

## FIGURE 32H

DNA sequence encoding preprotein 14 (SEQ ID NO: 91)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 2 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X2 + sPD-1 variant + Stop Codon.

GCCACCATGGACATGAGAGTGCCTGCTCAGCTGCTGGGACTGCTGCTGTTGTGGTTG  
AGAGGCGCCAGATGCATCACCTGTCTCCACCTATGTCCGTGGAACACGCCGAC  
ATCTGGGTCAAGTCTTACAGCCTGTACTCCAGAGAGCGGTACATCTGCAACTCC  
GGCTTCAAGAGAAAAGGCCGGCACCTCTAGCCTGACCGAGTGCGTGCTGAACAA  
GGCCACCAATGTGGCCCACTGGACCACACCTAGCCTGAAGTGCATCAGATCTGG  
GGGGGGTGGGTTCAGGTGGTGGGAGTGGCGGAGGTGGATCAGGTGGATCCGGTCAAAAT  
TGGGTCAACGTGATCTCCGACCTGAAGAAGATCGAGGACCTGATCCAGTCCATGCACA  
TCGACGCTACCTGTACACCGAGTCCGACGTGCACCCTTCCTGTAAAGTGACCGCCAT  
GAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCCCTGGAATCCGGCGACGCCTCTATC  
CACGACACCGTGGAAGAACCTGATCATCTGGCCAACAACCTCCCTGTCCAGCAACGGCA  
ACGTGACCGAGTCTGGCTGCAAGAGTGGAGGAACTGGAAGAGAAAGACATCAAAG  
AGTTCTCCAGTCTTCGTGCACATCGTGACAGATGTTTCATCAACACCTCCGGCGGATC  
TGGTGGCGGTGGATCCGAGTCTAAGTACGGCCCTCCTTGTCCTCCATGTCTGCTCC  
AGAGTTTCTCGGCGGACCCTCCGTGTTCTCTGTTTCTCCAAAGCCTAAGGACACCCT  
GATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTTCGATGTGTCCCAAGAGGA  
TCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGA  
CCAAGCCTAGAGAGGAACAGTTCAACTCCACCTACAGAGTGGTGTCCGTGCTGACCG  
TGCTGCACACGAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG  
GGCCTGCCTTCCAGCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTAGGGA  
ACCCAGGTTTACACCCTGCCTCCAAGCCAAGAGGAAATGACCAAGAACCAGGTGT  
CCCTGACCTGCCTGGTCAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGGAGAG  
CAATGGCCAGCCTGAGAACAACCTACAAGACAACCCCTCCTGTGCTGGACTCCGACGG  
CTCCTTCTTTCTGTACTCCCGCCTGACCGTGGACAAGTCCAGATGGCAAGAGGGCAA  
CGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGTC  
CCTGTCTCTGTCCCTGGGCAAATCTGGCGGAGGTGGAAGTGGCGGTGGCGGATCTTT  
GGACTCTCCTGACAGACCTTGGAACCCTCCAACCTTCTCTCCCGCTCTGCTGGT  
GGTTACCGAGGGCGACAATGCCACCTTCACCTGTTCTTCAGCAACACCAGCGA  
GTCTTTGTGCTGAACTGGTACAGAATGTCCCCTAGCAACCAGACCGACAAGCT  
GGCCGCCTTTCCTGAGGACAGATCTCAGCCAGGCCAGGACTGCCGGTTCAGAG  
TTACCCAGCTGCCTAACGGCCGGGACTTCCACATGTCTGTCTGTCGGGGCCAGA  
AGAAACGACTCTGGCACCTACCTGTGCTCCGCTATTGTGCTGGCCCTAAGATC  
CAGATCAAAGAGAGCCTGCGGGTCGAGCTGAGAGTGACAGAGCGTAGAGCTGA  
GGTGCCACCGCTCATCTTCACCTTCTCCAAGACCTGCCGGCCAGTTTCAGAC  
CCTCGTGTGATAA

## FIGURE 32I

DNA sequence encoding preprotein 15 (SEQ ID NO: 92)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 3 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X2 + sPD-1 variant + Stop Codon.

GCCACCATGGACATGAGAGTGCCTGCTCAGCTGCTGGGACTGCTGCTGTTGTGGTTG  
AGAGGCGCCAGATGCATCACCTGTCTCCACCTATGTCCGTGGAACACGCCGAC  
ATCTGGGTCAAGTCTACAGCCTGTACTCCAGAGAGCGGTACATCTGCAACTCC  
GGCTTCAAGAGAAAAGGCCGGCACCTCTAGCCTGACCGAGTGCGTGCTGAACAA  
GGCCACCAATGTGGCCCACTGGACCACACCTAGCCTGAAGTGCATCAGATCTGG  
CGGAGGAGGAAGTGGCGGTAGCGGAGGTAGCGGTGGAGGCGGTAGTGGCTCACAAAAT  
TGGGTCAACGTGATCTCCGACCTGAAGAAGATCGAGGACCTGATCCAGTCCATGCACA  
TCGACGCTACCTGTACACCGAGTCCGACGTGCACCCTTCCTGTAAAGTGACCGCCAT  
GAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCCCTGGAATCCGGCGACGCCTCTATC  
CACGACACCGTGGAACCTGATCATCTGGCCAACAACCTCCCTGTCCAGCAACGGCA  
ACGTGACCGAGTCTGGCTGCAAGAGTGGAGGAACTGGAAGAGAAAGACATCAAG  
AGTTCTCCAGTCTTCGTGCACATCGTGAGATGTTTCATCAACACCTCCGGCGGATC  
TGGTGGCGGTGGATCCGAGTCTAAGTACGGCCCTCCTTGTCCTCCATGTCTGCTCC  
AGAGTTTCTCGGCGGACCCTCCGTGTTCTCTGTTTCTCCAAAGCCTAAGGACACCCT  
GATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTCGATGTGTCCCAAGAGGA  
TCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGA  
CCAAGCCTAGAGAGGAACAGTTCAACTCCACCTACAGAGTGGTGTCCGTGCTGACCG  
TGCTGCACACGAGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG  
GGCCTGCCTTCCAGCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTAGGGA  
ACCCAGGTTTACACCCTGCCTCCAAGCCAAGAGGAAATGACCAAGAACCAGGTGT  
CCCTGACCTGCCTGGTCAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGGAGAG  
CAATGGCCAGCCTGAGAACAACTACAAGACAACCCCTCCTGTGCTGGACTCCGACGG  
CTCCTTCTTTCTGTACTCCCGCCTGACCGTGGACAAGTCCAGATGGCAAGAGGGCAA  
CGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGTC  
CCTGTCTCTGTCCCTGGGCAAATCTGGCGGAGGTGGAAGTGGCGGTGGCGGATCTTT  
GGACTCTCCTGACAGACCTTGGAACCCTCCAACCTTCTCTCCCGCTCTGCTGGT  
GGTTACCGAGGGCGACAATGCCACCTTCACCTGTTCTTCAGCAACACCAGCGA  
GTCTTTGTGCTGAACTGGTACAGAATGTCCCCTAGCAACCAGACCGACAAGCT  
GGCCGCCTTTCCTGAGGACAGATCTCAGCCAGGCCAGGACTGCCGGTTCAGAG  
TTACCCAGCTGCCTAACGGCCGGGACTTCCACATGTCTGTCTGTCGGGGCCAGA  
AGAAACGACTCTGGCACCTACCTGTGCTCCGCTATTGTGCTGGCCCTAAGATC  
CAGATCAAAGAGAGCCTGCGGGTCGAGCTGAGAGTGACAGAGCGTAGAGCTGA  
GGTGCCACCGCTCATCTTCACCTTCTCCAAGACCTGCCGGCCAGTTTCAGAC  
CCTCGTGTGATAA

## FIGURE 32J

DNA sequence encoding preprotein 19 (SEQ ID NO: 93)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 1 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X3 + sPD-1 variant + Stop Codon.

GCCACCATGGACATGAGAGTGCCTGCTCAGCTGCTGGGACTGCTGCTGTTGTGGTTG  
AGAGGCGCCAGATGCATCACCTGTCTCCACCTATGTCCGTGGAACACGCCGAC  
ATCTGGGTCAAGTCTACAGCCTGTACTCCAGAGAGCGGTACATCTGCAACTCC  
GGCTTCAAGAGAAAAGGCCGGCACCTCTAGCCTGACCGAGTGCGTGCTGAACAA  
GGCCACCAATGTGGCCCACTGGACCACACCTAGCCTGAAGTGCATCAGATCCGG  
TGGTGGAGGTAGCGGGGGCGGTGGATCAGGAGGAGGGAGTGGGGGAAGTGGCCAAAAT  
TGGGTCAACGTGATCTCCGACCTGAAGAAGATCGAGGACCTGATCCAGTCCATGCACA  
TCGACGCTACCTGTACACCGAGTCCGACGTGCACCCTTCCTGTAAAGTGACCGCCAT  
GAAGTGCTTTCTGCTGGAAGTGCAAGTGATCTCCCTGGAATCCGGCGACGCCTCTATC  
CACGACACCGTGGAACCTGATCATCTGGCCAACAACCTCCCTGTCCAGCAACGGCA  
ACGTGACCGAGTCTGGCTGCAAGAGTGCGAGGAACTGGAAGAGAAGAACATCAAAG  
AGTTCTCCAGTCTTCGTGCACATCGTGACAGATGTTTCATCAACACCTCCGGCGGATC  
TGGTGGCGGTGGATCCGAGTCTAAGTACGGCCCTCCTTGTCCTCCATGTCTCTGCTCC  
AGAGTTTCTCGGCGGACCCTCCGTGTTCTCTGTTTCTCCAAAGCCTAAGGACACCCT  
GATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTCGATGTGTCCCAAGAGGA  
TCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACAACGCCAAGA  
CCAAGCCTAGAGAGGAACAGTTCAACTCCACCTACAGAGTGGTGTCCGTGCTGACCG  
TGCTGCACACGAGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG  
GGCCTGCCTTCCAGCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTAGGGA  
ACCCAGGTTTACACCCTGCCTCCAAGCCAAGAGGAAATGACCAAGAACCAGGTGT  
CCCTGACCTGCCTGGTCAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGGAGAG  
CAATGGCCAGCCTGAGAACAACTACAAGACAACCCCTCCTGTGCTGGACTCCGACGG  
CTCCTTCTTTCTGTAATCCCGCCTGACCGTGGACAAGTCCAGATGGCAAGAGGGCAA  
CGTGTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGTC  
CCTGTCTCTGTCCCTGGGCAAATCTGGCGGAGGTGGAAGTGGCGGAGGCGGTTTCAGG  
TGGTGGTGGTTCTCTGGACTCTCCCGACAGACCTTGGAACCCTCCAACCTTCTCT  
CCCGCTCTGCTGGTGGTTACCGAGGGCGACAATGCCACCTTCACCTGTTCTCTC  
AGCAACACCAGCGAGTCCTTTGTGCTGAACTGGTACAGAATGTCCCCTAGCAAC  
CAGACCGACAAGCTGGCCGCCTTTCCTGAGGACAGATCTCAGCCAGGCCAGGA  
CTGCCGGTTCAGAGTTACCCAGCTGCCTAACGGCCGGGACTTCCACATGTCTGT  
CGTGCGGGCCAGAAGAAACGACTCTGGCACCTACCTGTGCTCCGCTATTGTGCT  
GGCCCCTAAGATCCAGATCAAAGAGAGCCTGCGGGTCGAGCTGAGAGTGACAG  
AGCGTAGAGCTGAGGTGCCCACCGCTCATCCTTCACCTTCTCCAAGACCTGCCG  
GCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 32K

DNA sequence encoding preprotein 20 (SEQ ID NO: 94)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 2 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X3 + sPD-1 variant + Stop Codon.

GCCACCATGGACATGAGAGTGCCTGCTCAGCTGCTGGGACTGCTGCTGTTGTGGTTG  
AGAGGCGCCAGATGCATCACCTGTCCTCCACCTATGTCCGTGGAACACGCCGAC  
ATCTGGGTCAAGTCCTACAGCCTGTACTCCAGAGAGCGGTACATCTGCAACTC  
CGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCTGACCGAGTGCGTGCTGAACA  
AGGCCACCAATGTGGCCCACTGGACCACACCTAGCCTGAAGTGCATCAGATCTG  
GGGGGGGTGGGTCAGGTGGTGGGAGTGGCGGAGGTGGATCAGGTGGATCCGGTCAAAA  
TTGGGTCAACGTGATCTCCGACCTGAAGAAGATCGAGGACCTGATCCAGTCCATGCAC  
ATCGACGCTACCCTGTACACCGAGTCCGACGTGCACCCCTTCTGTAAAGTGACCGCCA  
TGAAGTGCTTTCTGCTGGAAGTGAAGTGATCTCCCTGGAATCCGGCGACGCCTCTAT  
CCACGACACCGTGGAACCTGATCATCCTGGCCAACAACCTCCCTGTCCAGCAACGGC  
AACGTGACCGAGTCTGGCTGCAAGAGTGCAGGAACTGGAAGAGAAGAACATCAAA  
GAGTTCTCTCCAGTCCTTCGTGCACATCGTGACAGATGTTTCATCAACACCTCCGGCGGAT  
CTGGTGGCGGTGGATCCGAGTCTAAGTACGGCCCTCCTTGTCTCTCCATGTCTCTGCT  
CCAGAGTTTCTCGGCGGACCCTCCGTGTTCTCTGTTTCTCTCCAAAGCCTAAGGACACC  
CTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTTCGATGTGTCCCAAGAG  
GATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACAACGCCAA  
GACCAAGCCTAGAGAGGAACAGTTCAACTCCACCTACAGAGTGGTGTCCGTGCTGA  
CCGTGCTGCACCAGGATTGGCTGAACGGCAAAAGAGTACAAGTGCAAGGTGTCCAAC  
AAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTAG  
GGAACCCAGGTTTACACCCTGCCTCCAAGCCAAGAGGAAATGACCAAGAACCAGG  
TGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGG  
AGAGCAATGGCCAGCCTGAGAACAATAACAAGACAACCCCTCCTGTGCTGGACTCC  
GACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGGACAAGTCCAGATGGCAAGAG  
GGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAG  
AAGTCCCTGTCTCTGTCCCTGGGCAAATCTGGCGGAGGTGGAAGTGGCGGAGGCGGTT  
CAGGTGGTGGTGGTTCTCTGGACTCTCCCGACAGACCTTGGAACCCTCCAACCTT  
CTCTCCCGCTCTGCTGGTGGTTACCGAGGGCGACAATGCCACCTTCACCTGTTT  
CTTCAGCAACACCAGCGAGTCCTTTGTGCTGAACTGGTACAGAATGTCCCTTAG  
CAACCAGACCGACAAGCTGGCCCGCCTTTCCTGAGGACAGATCTCAGCCAGGCC  
AGGACTGCCGGTTCAGAGTTACCCAGCTGCCTAACGGCCGGGACTTCCACATG  
TCTGTCGTGCGGGCCAGAAGAAACGACTCTGGCACCTACCTGTGCTCCGCTAT  
TGTGCTGGCCCCCTAAGATCCAGATCAAAGAGAGCCTGCGGGTCGAGCTGAGAG  
TGACAGAGCGTAGAGCTGAGGTGCCACCGCTCATCCTTCACCTTCTCCAAGA  
CCTGCCGGCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 32L

DNA sequence encoding preprotein 21 (SEQ ID NO: 95)

Kozak Sequence + Signal peptide + Human IL-15R alpha sushi + Linker variant 3 + Human IL-15 + GS linker + Human IgG4 Fc + GS linker X3 + sPD-1 variant + Stop Codon.

GCCACCATGGACATGAGAGTGCCTGCTCAGCTGCTGGGACTGCTGCTGTTGTGGTTG  
AGAGGCGCCAGATGCATCACCTGTCCTCCACCTATGTCCGTGGAACACGCCGAC  
ATCTGGGTCAAGTCTTACAGCCTGTACTCCAGAGAGCGGTACATCTGCAACTC  
CGGCTTCAAGAGAAAGGCCGGCACCTCTAGCCTGACCGAGTGCGTGCTGAACA  
AGGCCACCAATGTGGCCCACTGGACCACACCTAGCCTGAAGTGCATCAGATCTG  
GCGGAGGAGGAAGTGGCGGTAGCGGAGGTAGCGGTGGAGGCGGTAGTGGCTCAGAAA  
TTGGGTCAACGTGATCTCCGACCTGAAGAAGATCGAGGACCTGATCCAGTCCATGCAC  
ATCGACGCTACCCTGTACACCGAGTCCGACGTGCACCCCTTCTGTAAAGTGACCGCCA  
TGAAGTGCTTTCTGCTGGAAGTGCAGTGATCTCCCTGGAATCCGGCGGACGCTCTAT  
CCACGACACCGTGGAAGAACCTGATCATCCTGGCCAACAACCTCCCTGTCCAGCAACGGC  
AACGTGACCGAGTCTGGCTGCAAGAGTGGGAGGAACTGGAAGAGAGAAGACATCAAA  
GAGTTCCTCCAGTCTTCTGTCACATCGTGACAGATGTTTCATCAACACCTCCGGCGGAT  
CTGGTGCGGTGGATCCGAGTCTAAGTACGGCCCTCCTTGTCTCTCCATGTCTCTGCT  
CCAGAGTTTCTCGGCGGACCCCTCCGTGTTCTCTGTTTCTCTCCAAAGCCTAAGGACACC  
CTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTTCGATGTGTCCCAAGAG  
GATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAA  
GACCAAGCCTAGAGAGGAACAGTTCAACTCCACCTACAGAGTGGTGTCCGTGCTGA  
CCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC  
AAGGGCCTGCCTTCCAGCATCGAAAAGACCATCTCCAAGGCCAAGGGCCAGCCTAG  
GGAACCCAGGTTTACACCCTGCCTCCAAGCCAAGAGGAAATGACCAAGAACCAGG  
TGTCCCTGACCTGCCTGGTCAAGGGCTTCTACCCTTCCGATATCGCCGTGGAATGGG  
AGAGCAATGGCCAGCCTGAGAACAACTACAAGACAACCCCTCCTGTGCTGGACTCC  
GACGGCTCCTTCTTTCTGTACTCCCGCCTGACCGTGGACAAGTCCAGATGGCAAGAG  
GGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAG  
AAGTCCCTGTCTCTGTCCCTGGGCAAACTGGCGGAGGTGGAAGTGGCGGAGGCGGT  
CAGGTGGTGGTGGTTCTCTGGACTCTCCCGACAGACCTTGGAACCCTCCAACCTT  
CTCTCCCGCTCTGCTGGTGGTTACCGAGGGCGACAATGCCACCTTCACCTGTTT  
CTTCAGCAACACCAGCGAGTCTTTGTGCTGAACTGGTACAGAATGTCCCCTAG  
CAACCAGACCGACAAGCTGGCCGCCTTTCCTGAGGACAGATCTCAGCCAGGCC  
AGGACTGCCGGTTCAGAGTTACCCAGCTGCCTAACGGCCGGGACTTCCACATG  
TCTGTCTGCGGGCCAGAAGAAACGACTCTGGCACCTACCTGTGCTCCGCTAT  
TGTGCTGGCCCCTAAGATCCAGATCAAAGAGAGCCTGCGGGTCGAGCTGAGAG  
TGACAGAGCGTAGAGCTGAGGTGCCACCGCTCATCCTTCACCTTCTCCAAGA  
CCTGCCGGCCAGTTTCAGACCCTCGTGTGATAA

## FIGURE 33

## Wild Type ECD of Human PD-1 (SEQ ID NO:96)

PGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKL  
 AAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNSGTYLCGAISLAPKAQIKESL  
 RAELRVTERRAEVPTAHPSPSPRPAGQFQTLV

## FIGURE 34

## Exemplary AB002; sPD-1 variant/IL-15 bispecific (SEQ ID NO: 97)

Signal peptide 2 + Human IL-15R alpha sushi + *Linker* + Human IL-15 + GS linker + Human IgG4 Fc + *GS linker X2* + sPD-1 variant

MDMRVPAQLLGLLLLWLRGARCITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKR  
KAGTSSLTECVLNKATNVAHWTTPSLKCIRSGGSGGGGSGGGSGGGGSLQNWVNVIS  
DLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLELOVISLESGDASIHDTVENLII  
LANNLSNNGNVTESGCKECELEEKNIKEFLQSFVHIVQMFINTSGGSGGGGSESKYG  
PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE  
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG  
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTTPVLDS  
DGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLKSGGGGSGGGGS  
LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAA  
FPEDRSOPGQDCRFRVTQLPNGRDFHMSVVRARRNSGTYLCSAIVLAPKIQIKESL  
RVELRVTERRAEVPTAHPSPSPRPAGQFQTLV